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Abstract: Systemic and local inflammation in relation to the resident microbiota of the 
human gastro-intestinal (GI) tract and administration of probiotics are the main themes of 
the present review. The dominating taxa of the human GI  tract and their potential for 
aggravating  or  suppressing  inflammation  are  described.  The  review  focuses  on  human 
trials with probiotics and does not include in vitro studies and animal experimental models. 
The applications of probiotics considered are systemic immune-modulation, the metabolic 
syndrome, liver injury, inflammatory bowel disease, colorectal cancer and radiation-induced 
enteritis. When the major genomic differences between different types of probiotics are 
taken into account, it is to be expected that the human body can respond differently to the 
different species and strains of probiotics. This fact is often neglected in discussions of the 
outcome of clinical trials with probiotics.  
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1. Inflammation 
Inflammation is a defence reaction of the body against injury. The word inflammation originates 
from the Latin word ―inflammatio‖ which means fire, and traditionally inflammation is characterised 
by  redness,  swelling,  pain,  heat  and  impaired  body  functions.  Redness  and  heat  are  caused  by 
increased blood flow, swelling by accumulation of fluid, and pain by the swelling, but also by release 
of compounds giving rise to nerve signals. Impaired functions are caused by different reasons but, in a 
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certain analogy to fire, inflammation is devastating in order to clear away harmful agents and therefore 
prepare the ground for re-growth (healing).  
Inflammation  can  be  triggered  off  by  both  internal  and  external  factors.  Powerful  triggers  for 
inflammation are the presence of microorganisms in sites where they do not belong. Microorganisms 
contain structures alien to the body. Bacteria and fungi, for example, have cell walls in contrast to 
human cells that lack these structures, and viruses have unique forms of DNA and RNA. Cells and 
molecules  involved  in  the  inflammatory  defence  system  react  immediately  against  these  foreign 
elements; they are danger signals to the body. In addition, injuries to body tissue and cells trigger 
inflammation. When the body cells are damaged, compounds that are normally hidden within the cells 
are released and work as endogenous danger signals. All forms of immune reactions will lead to 
activation  of  the  inflammatory  defence  system.  Consequently,  inflammation  can  be  started  by 
infections, decomposition of body tissue by trauma (for example, due to surgery or accidents) and 
autoimmunity or allergy. In autoimmunity the specific immune system attacks body cells and tissue 
and releases the inflammation, and in allergy the inflammation is provoked by the specific immune 
system being activated against different types of harmless compounds in the environment, e.g., food 
and pollen.  
The  process  of  inflammation  is  initiated  by  cells  already  present  in  the  tissue,  e.g.,  resident 
macrophages, dendritic cells and mast cells. Danger signals trigger these cells into activation, and 
inflammatory mediators are released, which starts the process responsible for the clinical signs of 
inflammation. The process of inflammation involves four stages:  
(i)  Blood vessels widen, resulting in increased blood flow (causing the redness and increased heat);  
(ii)  Permeability of the blood vessels is increased, which results in an outflow of fluid and plasma 
proteins into the tissue, manifesting itself as swelling;  
(iii) White blood cells are recruited from the blood circulation to the tissue;  
(iv) The  metabolism is  adjusted, for  example  by increased  levels of glucose in the  blood, and 
symptoms such as fever, fatigue and loss of appetite can occur. 
When the process of inflammation has been initiated, it will proceed along a certain course of 
events until the source of the inflammation has been erased and the healing process can start. However, 
if the cause of the inflammation cannot be eliminated, the inflammation will continue, and then it will 
often vary in intensity over time.  
In acute inflammation, there will be an accumulation of neutrophil granulocytes (neutrophils) in the 
inflamed  tissue,  while  in  chronic  inflammation  there  will  be  an  accumulation  of  lymphocytes, 
macrophages  and  plasma  cells  in  the  tissue  and  also  infiltrating  connection  tissue.  In  an  allergic 
reaction, however, there will be a rapid accumulation of eosinophil granulocytes (eosinophils) and  
T-lymphocytes, and sometimes also neutrophils. A representative example of a situation leading to 
acute inflammation is a bacterial infection, but cell death at infarct of the heart or decomposition of 
cancer  tumours  will  also  lead  to  acute  inflammation.  Typical  causes  of  chronic  inflammation  are 
infections  with  intracellular  bacteria,  autoimmune  diseases,  contact  allergy  and  reactions  against 
foreign elements [1]. 
In an acute inflammatory response, the concentration of acute phase proteins such as C reactive 
protein (CRC) and serum amyloid A protein (SAA) can increase steeply and rise to 10,000-fold above Nutrients 2011, 3  
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base-line [2]. However, different markers for acute inflammation can also be monitored more closely 
where more subtle and inflexible systemic alterations are taken into consideration. This type of slight 
elevation  from  the  norm  can  be  called  ―low-grade  inflammation‖,  or  ―subclinical  inflammation‖. 
Consequently, in this type of condition the sharp short-term fluctuations of inflammatory markers are 
ignored; instead, long-term systemic concentrations of the markers are considered, especially if they 
correlate with more obvious risk factors such as, for example, blood cholesterol and blood pressure. 
Low-grade  systemic  inflammation,  mainly  characterised  by  increased  CRP,  is  associated  with  an 
increased  risk  of  cardiovascular  disease  [3],  and  obese  individuals  have  higher  CRP  levels  than 
subjects of normal weight [4,5]. 
The intestinal immune system has developed a tightly regulated control to optimise the protection 
against pathogens, while at the same time avoiding unnecessary immune activity. The intestine is a 
primary site of foreign antigen encounter and it is associated with several types of lymphoid organs 
collectively referred to as gut-associated lymphoid tissue (GALT). GALT is the largest collection of 
lymphoid tissues in the body and consists of organised lymphoid tissues comprising mesenteric lymph 
nodes, Payer´ s patches, isolated lymphoid follicles, and cryptopatches, as well as diffusely scattered 
lymphocytes and dendritic cells in the lamina propria and intestinal epithelium [6–8]. Some of them, 
such as Payer’s patches and the isolated lymphoid follicles, are within the mucosa itself. In addition, 
intestinal  lymph  drains  into  the  mesenteric  lymph  nodes,  which  constitute  a  key  checkpoint  to 
determine the anatomical location of tolerogenic or inflammatory responses [9]. 
In  inflammation,  macrophages  have  three  major  functions,  namely:  (i)  antigen  presentation, 
(ii) phagocytosis and (iii) immune-modulation through production of various cytokines and growth 
factors. Monocytes/macrophages produce a wide range of biologically active molecules participating 
in  both  beneficial  and  detrimental  outcomes  of  inflammatory  reactions.  They  are  also  able  to 
phagocytose and destroy infectious agents. Therefore, monocytes/macrophages play a critical role in 
initiation,  maintenance,  and  resolution  of  inflammation  [10,11].  Macrophages  form  varying 
phenotypes  depending  on  what  signals  they  encounter  [12].  Different  subsets  of  macrophages  
express  different  patterns  of  chemokines,  surface  markers  and  metabolic  enzymes.  Classically 
activated  macrophages  (proinflammatory  M1)  induced  by  proinflammatory  mediators,  such  as 
lipopolysaccharide (LPS), IL-1β and IFN-γ, produce proinflammatory cytokines (TNF-α, IFN-γ, IL-6 
and IL-12) and generate reactive oxygen species [13,14]. In contrast, M2 macrophages, alternatively 
activated by exposure to, for example, IL-4, IL-13 and IL-10, produce less proinflammatory cytokines 
than M1, and instead produce more components signalling anti-inflammation, for example, IL-10, 
TGF-β and IL-1 receptor antagonist [14]. M2 macrophages are believed to participate in the blockade 
of inflammatory responses and promotion of tissue repair and type II immunity [15]. Consequently, 
different macrophage subsets have different roles in both inflammation and modulation of the immune 
response or tolerance. 
Microbial colonisation of the GI tract affects the composition of GALT. Immediately after exposure 
to  luminal  microorganisms,  the  number  of  intraepithelial  lymphocytes  expands  greatly  [16,17], 
germinal  centres with  immunoglobulin-producing cells arise rapidly in  follicles and  in the lamina 
propria [18], and concentrations of immunoglobulin increase substantially in serum [19]. 
There  is  a  complex  relationship  between  the  intestinal  immune  system  and  the  resident  GI 
microbiota and it is crucial for the epithelial cells and the mucosal immune system to distinguish Nutrients 2011, 3  
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between  pathogenic  and  non-pathogenic  agents.  Intestinal  epithelial  cells  are  capable  of  detecting 
bacterial antigens and initiating and regulating both innate and adaptive immune responses. Signals 
from  bacteria  can  be  transmitted  to  adjacent  immune  cells  such  as  macrophages,  dendritic  cells  
and  lymphocytes  through  molecules  expressed  on  the  epithelial  cell  surface,  such  as  major  
histo-compatibility  complex  I  and  II  molecules  and  Toll-like  receptors  (TLRs)  [20,21].  TLRs  
alert  the  immune  system  to  the  presence  of  highly  conserved  microbial  antigens  often  termed  
―pathogen-associated  molecular  patterns‖  (PAMPs)  present  on  most  microorganisms.  Examples  of 
PAMPs  include  lipopolysaccharides  (LPS),  peptidoglycan,  flagellin,  and  microbial  nucleic  acids. 
TRLs are so named because of their similarity to a receptor first identified in the fruit fly Drosophila 
melanogaster, a protein coded by the Toll-gene (―toll‖ means fantastic in German). At least ten types 
of  human  TLRs  are  known.  In  healthy  adults,  TLRs  are  expressed  in  most  tissues,  including 
myelomonocytic cells, dendritic cells and endothelial and epithelial cells. Interaction of TLRs and 
bacterial  molecular  patterns  results  in  activation  of  a  complex  intracellular  signalling  cascade,  
up-regulation of inflammatory genes, production of pro-inflammatory cytokines and interferons, and 
recruitment of myeloid cells. It also stimulates expression of co-stimulatory molecules required to 
induce an adaptive immune response of antigen presenting cells [22]. Epithelium in, for example, 
colon shows a comparably high level of expression of TLR3, TLR4, TLR5, and TLR7, with TLR3 
being the most abundant [23], while cervical and vaginal epithelial cells have a higher expression of 
TLR1, TLR2, TLR3, TLR5 and TLR6 [24]. TLR4 recognises lipopolysaccharide (LPS) [25,26], a 
constituent of the cell wall of Gram-negative bacteria, while TLR2 reacts with a wider spectrum of 
bacterial products such as lipoproteins, peptidoglycans and lipoteichoic acid which can be found in 
both Gram-positive and Gram-negative bacteria [27,28]. 
Besides the TLRs there is another family of membrane-bound receptors for detection of proteins 
called  NOD-like  receptors  or  ―nucleotide-binding  domain,  leucine-rich  repeat  containing‖  proteins 
(NLRs). The best characterised members are NOD1 and NOD2, but more than twenty different NLRs 
have been identified. NRLs are located in the cytoplasm and are involved in the detection of bacterial 
PAMPs that enter the mammalian cell. NRLs are especially important in tissues where TLRs are 
expressed at low levels [29]. This is the case in the epithelial cells of the GI tract where the cells are in 
constant contact with the microbiota, and the expression of TLRs must be down-regulated in order to 
avoid over-stimulation. On the other hand, if these epithelial gut cells become infected with invasive 
bacteria or bacteria interacting directly with the plasma membrane, they will come into contact with 
NLRs  and  defence  mechanisms  can  be  activated  [30].  NLRs  are  also  involved  in  sensing  other 
endogenous warning signals which will result in the activation of inflammatory signalling pathways, 
such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs). Both NOD1 
and  NOD2  recognise  peptidoglycan  moieties  found  in  bacteria.  NOD1  can  sense  peptidoglycan 
moieties  containing  meso-diaminopimelic  acid,  which  primarily  are  associated  to  gram-negative 
bacteria.  NOD2  senses  the  muramyl  dipeptide  motif  that  can  be  found  in  a  wider  range  of  
bacteria  [31,32].  The  ability  of  NRLs  to  regulate,  for  example,  nuclear  factor-kappa  B  (NF-κB) 
signalling  and  interleukin-1-beta  (IL-1β)  production,  indicates  that  they  are  important  for  the 
pathogenesis of inflammatory human diseases, such as Crohn’s disease. The role of NLRs in innate 
immunity and inflammatory diseases has been thoroughly reviewed by Chen et al. [33]. Nutrients 2011, 3  
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NLRs and TLRs interplay in the regulation of the inflammatory response towards bacteria. The 
expression level of TLRs on the gut epithelium is sophisticated in order to prevent over-stimulation 
and permanent activation. The GI microbiota can alter this response and the interaction can occur in 
different ways. The follicle-associated epithelium, which covers Peyer’s patches, is located along the 
small intestine and is particularly abundant in the ileum. The epithelium harbours shorter villi and 
contains specialised cells, called microfold cells (M cells). M cells have numerous microfolds on the 
epithelial side and are specialised in capturing soluble antigens, apoptotic epithelial cells or bacteria 
from the luminal compartment, and transport them to Peyer’s patches for sampling by dendritic cells or 
destruction by macrophages [7]. Dendritic cells may present antigen locally to T cells, migrate to  
T cell zones or to mesenteric lymph nodes, or interact with memory B cells [34]. Both pathogenic and 
non-pathogenic bacteria can also enter the mucosal tissue through lamina propria associated dendritic 
cells, which extend their dendrites through epithelial cell tight junctions [6]. Also, the intraepithelial 
lymphocytes located in the epithelium might recognise microbial antigens [35].  
In addition to intestinal epithelial cells, the epithelium includes specialised cells such as goblet 
cells, which secrete the protective mucus layer limiting the contact between bacteria and epithelial 
cells,  and  Paneth  cells,  which  reside  in  the  crypts  of  the  small  intestine  and  secrete  bactericidal 
peptides [36]. Secretory IgA is the predominant class of immunoglobulin found in intestinal secretions. 
It is produced by plasma cells residing in the lamina propria and is transported to the lumen by the 
polyimmunoglobulin receptor. IgA molecules contribute to specific immunity by capturing antigens, 
thereby inhibiting mucosal penetration [37]. 
Inflammation is a consequence of allergy and autoimmune diseases such as arthritis, diabetes type 1, 
multiple sclerosis and Crohn’s disease, but a low-grade systemic inflammation also characterises the 
metabolic syndrome and the ageing body. Long-term inflammation increases the risk for heart and 
cardiovascular diseases, and non-alcoholic fatty liver disease (NAFLD). It also increases the risk of 
cancer and dementia. Diabetes 2 and obesity are indeed characterised by a low-grade inflammation but 
it is still unclear if the inflammation is the cause of the condition or just a consequence of it. The 
bacterial flora (microbiota) of the gut is significant in relation to inflammation, and so favourable 
influence  on  the  composition  of  the  gut  microbiota  can  be  a  strategy  to  mitigate  inflammation. 
Ingesting  probiotics  (health-beneficial  bacteria)  can  affect  the  composition  of  the  resident  gut 
microbiota,  but  probiotics  may  also  have  more  direct  effects  on  the  immune  system  and  the 
permeability  of  the  mucosa.  The  better  the  barrier  effect  of  the  mucosa  the  smaller  the  risk  of 
translocation of pro-inflammatory components originating from the gut microbiota.  
2. Human Gastrointestinal Microbiota 
2.1. Viable Count, Metagenomics and the Phylogenetic Core 
The  human  GI  microbiota  starts  already  in  the  mouth,  which  harbours  a  viable  count  of  
10
8–10
10 colony forming units (CFU) of bacteria per g saliva. These bacteria are constantly fed to the 
GI channel by the swallowing reflex. The numbers are reduced in the stomach (around 10
3 CFU/g 
gastric juice), duodenum and jejunum (10
2–10
4 CFU/g content), and then increase again in ileum and 
colon (around 10
10 CFU/g content and 10
10–10
12 CFU/g content, respectively). These bacteria are of Nutrients 2011, 3  
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different types and, traditionally, attempts to identify them have been done by pure-culture technique, 
i.e.,  isolates  are  cultured  at  the  laboratory  and  both  phenotypic  and  genotypic  characteristics  are 
studied in pure cultures. Current methods are more directed towards direct gene-identification, and 
mostly towards the 16S ribosomal RNA (rRNA) gene but, lately, ―shotgun‖ Sanger sequencing or 
massively parallel pyrosequencing have also been used in an attempt to obtain unbiased samples of all 
genes of a community [38]. The term ―metagenomics‖ is frequently used as a label for studies where 
more  or  less  all  the  genetic  material  is  recovered  and  identified  directly  from  environmental 
samples [39]. For example, the latter principle was used on faeces of 124 individuals, and each one of 
the individuals was shown to harbour at least 160 prevalent bacterial species in faeces [40]. Some 
species are found in many individuals and some are only found in a few. In an attempt to establish the 
existence  of  a  phylogenetic  ―core‖  of  the  microbiota  common  for  a  majority  of  individuals,  
Tap et al. [41] obtained 10,456 16S rRNA gene sequences by PCR-amplification and cloning from 
faeces of 17 individuals. 3180 operational taxonomic units (OTUs) were detected, but most of these 
only appeared in a few individuals, and only 2.1% of the OTUs were present in more than 50% of the 
faecal samples. On the other hand, most of the OTUs belonged to the phyla Firmicutes (about 80%), 
Bacteroidetes  (about  20%),  Actinobacteria  (about  3%),  Proteobacteria  (1%)  and  Verrumicrobia 
(0.1%). Consequently, when bacteria are identified on higher hierarchical levels of taxonomy such as 
phylum (division) and class, the individual differences between persons appear to be smaller while the 
differences between habitats within the same individual are more pronounced. For example, there is a 
significant  difference  in  the  composition  of  the  microbiota  between  the  oral  cavity  and  rectum 
(measured in stool) [42], and between jejunum and colon [43]. Furthermore, the general profile of the 
GI microbiota of an individual seems to be reasonably stable over time [42]. Frequently dominating 
genera in the human GI channel are summarised in Table 1. 
Table 1. Taxa dominating the bacterial microbiota of the GI-tract 
(1).  
Phyla/Division  Class  Family  Genus  Gram 
(2) 
Actinobacteria  Actinobacteria  Micrococcaceae  Rothia *  + 
Actinobacteria  Actinobacteria  Bifidobacteriaceae  Bifidobacterium  + 
         
Firmicutes  Bacilli  Streptoccaceae  Streptococcus  + 
Firmicutes  Bacilli  Lactobacillaceae  Lactobacillus  + 
Firmicutes  Bacilli  Enterococcaceae  Enterococcus  + 
Firmicutes  Negativicutes  Veillonellaceae  Veillonella  (−) 
Firmicutes  Negativicutes  Veillonellaceae  Dialiser  (−) 
Firmicutes  Clostridia  unclassified Clostridiales  Mogibacterium *  + 
Firmicutes  Clostridia  Peptostreptococcaceae  Peptostreptococcus *  + 
Firmicutes  Clostridia  Lachnospiraceae  Coprococcus  + 
Firmicutes  Clostridia  Lachnospiraceae  Dorea  + 
Firmicutes  Clostridia  Lachnospiraceae  Roseburia  (−) 
Firmicutes  Clostridia  Lachnospiraceae  Butyrivibrio  (−) 
Firmicutes  Clostridia  Ruminococcaceae  Ruminococcus  + 
Firmicutes  Clostridia  Ruminococcaceae  Faecalibacterium  + 
Firmicutes  Clostridia  Ruminococcaceae  Anaerotruncus  + 
Firmicutes  Clostridia  Ruminococcaceae  Subdoligranulum  + Nutrients 2011, 3  
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Table 1. Cont. 
Firmicutes  Clostridia  Clostridiaceae  Clostridium  + 
Firmicutes  Clostridia  Clostridiaceae  Blautia  + 
Firmicutes  Clostridia  Eubacteriaceae  Eubacterium  + 
Firmicutes  Clostridia  unclassified   Collinsella  + 
Firmicutes  Erysipelotrichia  Erysipelotrichaceae  Holdemania  + 
         
Proteobacteria  Betaproteobacteria  Alcaligenaceae  Sutterella  - 
Proteobacteria  Betaproteobacteria  Neisseriaceae  Neisseria  - 
Proteobacteria  Deltaproteobacteria  Desulfovibrionaceae  Bilophila  - 
Proteobacteria  Gammaproteobacteria  Pasteurellaceae  Haemophilus *  - 
Proteobacteria  Gammaproteobacteria  Enterobacteriaceae  Enterobacter *  - 
Proteobacteria  Gammaproteobacteria  Enterobacteriaceae  Serratia *  - 
Proteobacteria  Gammaproteobacteria  Enterobacteriaceae  Escherichia  - 
Proteobacteria  Gammaproteobacteria  Enterobacteriaceae  Klebsiella  - 
Proteobacteria  Gammaproteobacteria  Moraxellaceae  Acinetobacter  - 
Proteobacteria  Gammaproteobacteria  Pseudomonadaseae  Pseudomonas *  - 
Proteobacteria  Gammaproteobacteria  Cardiobacteriaceae  Cardiobacterium  - 
         
Bacteroidetes  Bacteroidia  Prevotellaceae  Prevotella *  - 
Bacteroidetes  Bacteroidia  Porphyromonadaceae  Porphyromonas *  - 
Bacteroidetes  Bacteroidia  Porphyromonadaceae  Parabacteroides  - 
Bacteroidetes  Bacteroidia  Bacteroidaceae  Bacteroides  - 
Bacteroidetes  Bacteroidia  Rikenellaceae  Alistipes   
         
Fusobacteria  Fusobacteria  Fusobacteriaceae  Fusobacterium  - 
         
Spirochaetae  Spirochaetes  Brachyspiraceae  Brachyspira  - 
         
Verrucomicrobia  Verrucomicrobiae  Verrucomicrobiaceae  Akkermansia  - 
(1) Genus identification has been made by direct gene identification, mostly of the 16S rRNA gene 
by cloning and sequencing; 
(2) Negative Gram-reaction within parenthesis means that the reaction is 
negative or variable. It has been shown for Butyrivibrio fibrisolvens that the negative gram-reaction 
is due to a thin cell wall and that the cell wall has Gram-positive characteristics [44]. Presumably 
this is also the case for the other Butyrivibrio spp. and perhaps also for other Firmicutes with 
Gram-negative reaction, i.e., they presumably do not contain lipopolysaccharides (LPS) and are 
usually associated with a Gram-negative cell wall. * Taxa typically found dominating in the upper 
GI tract (mouth to jejunum) but mostly much less pronounced in the distal GI tract (ileum to 
rectum); data from Pettersson et al. [45], Wang et al. [43], Hayashi et al. [46], Bik et al. [47], 
Lazarevic et al. [48], Li et al. [49], Nasidze et al. [50], Turnbaugh et al. [51] and Qin et al. [40]. 
2.2. Mouth 
According  to  Lazarevic  et  al.  [48],  dominating  phyla  in  the  oral  cavity  are  Firmicutes, 
Proteobacteria,  Actinobacteria,  Fusobacteria,  an  uncultured  group  of  16S  rRNA  gene  sequences 
labelled TM7 (TM for ―Torf, mittlere Schicht‖ = peat, middle layer) [52] and, to a lesser extent, Nutrients 2011, 3  
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Spirochaetes,  while  other  studies  have  found  Proteobacteria,  Firmicutes,  Actinobacteria,  and 
Bacteroidetes to be the dominant phyla [53]. The most frequently identified genera were Neisseria and 
Streptococcus, constituting about 70% of the sequences [48]. However, saliva samples from a larger 
number of individuals (10 individuals from each of 12 worldwide locations) showed that more than 
70%  of  16S  rRNA  gene  sequences  belonged to  the  genera  Streptococcus,  Prevotella,  Veillonella, 
Neisseria, Haemophilus, Rothia, Porphyromonas, and Fusobacterium [50]. A further 93 genera could 
be identified (known genera), but a phylogenetic analysis suggested that 64 unknown genera were also 
present in the saliva samples. The most frequent genus of all in the saliva was Streptococcus, which 
accounted for 23% of the sequences [50]. 
There is a high bacterial diversity in the mouth and huge differences between people, but mostly 
there seem to be relatively minor geographic differences [50]. Consequently, there was significantly 
more  variation  among  sequences from  different individuals than  among  sequences  from the  same 
individual, and there was not significantly more variation among individuals from different geographic 
locations than among individuals from the same location [50]. However, the two genera Enterobacter 
and  Serratia  (both  belonging  to  the  family  Enterobacteriaceae)  varied  significantly  in  frequency 
between locations, e.g., Enterobacter, which accounted for 28% of the sequences obtained in samples 
from Congo, was completely absent in samples from California, China, Germany, Poland, and Turkey. 
Serratia occurred at relatively high frequency in several individuals from Bolivia [50].  
2.3. Stomach 
The stomach has always been considered as a relatively harsh environment for bacteria and due to 
the low viable counts found there, it can always be debated whether the bacteria found are resident or 
transient (with the exception of Helicobacter pylori, the causative agent of gastric ulcers). An adult 
produces  about  two  litres  of  gastric  juice  daily  and  the  pH  in  lumen  is  below  2  under  fasting 
conditions, but 5–6 close to the epithelial cells due to the mucus layer. Based on 16S rRNA gene 
identification,  Bik  et  al.  [47]  found  that  the  dominating  phyla  on  the  gastric  mucosa  were 
Proteobacteria,  Firmicutes,  Actinobacteria,  Bacteroidetes,  and  Fusobacteria,  with  Helicobacter  
(all sequences were identified as H. pylori), Streptococcus and Prevotella as the most abundant genera. 
A similar pattern was seen by Li et al. [49] who found that the most common phyla were the same as 
reported  by  Bik  et  al.  [47],  except  in  another  order  with  Proteobacteria  as  the  least  frequently 
occurring  phylum.  Besides  the  genera  Streptococcus  and  Prevotella,  Neisseria,  Haemophilus  and 
Porphyromonas also represented a substantial proportion of the identified clones. These five phyla 
made up about 70% of the total number of clones [49]. 
2.4. Small Intestine 
2.4.1. Jejunum 
In jejunum, the mucosal microbiota of a middle-aged, healthy woman from Sweden was strongly 
dominated by Firmicutes (78% of clones), and to a lesser extent by Proteobacteria (13% of clones), 
Bacteroidetes,  Fusobacteria  and  Actinobacteria  [43].  Of  the  clones,  68%  were  identified  as 
Streptococcus (closely resembling Streptococcus mitis, Streptococcus salivarius, Streptococcus oralis, Nutrients 2011, 3  
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Streptococcus  parasanguinis  and  Streptococcus  anginosus),  and  3%  were  Gammaproteobacteria 
(Haemophilus, Escherichia, Acinetobacter and Pseudomonas) [43]. The Bacteroidetes clones were 
most  similar  to  Prevotella  melaninogenica  and  Prevotella  loescheii.  Other  Firmicutes  than 
Streptococcus found on the jejunum mucosa were Veillonella parvula, Mogibacterium neglectum and 
Peptostreptococcus anaerobius [43]. These results can be compared with the microbiota of jejunum 
content taken at autopsy of three elderly persons from Japan where also Proteobacteria and Firmicutes 
strongly  dominated,  and  with  smaller  proportions  of  Actinobacteria  and  Bacteroidetes  [46].  The 
Proteobacteria were mostly Klebsiella, and the Firmicutes clones were dominated by Lactobacillus, 
and only relatively few clones of Streptococcus were found [46]. 
2.4.2. Ileum 
In ileum, the mucosal microbiota of one middle-aged, healthy woman from Sweden was dominated 
by Bacteroidetes (49% of clones) and Firmicutes (39%) and, to a lesser extent, Verrucomicrobia, 
Proteobacteria and Fusobacteria (biopsies from distal ileum) [43]. The Bacteroidetes clones were 
mostly identified as Bacteroides thetaiotaomicron, Bacteroides vulgatus and Bacteroides uniformis 
while the Firmicutes mostly belonged to Clostridium clusters XIVa as defined by Collins et al. [54] 
(Coprococcus  catus,  Dorea  formicigenerans,  Ruminococcus  obeum,  Clostridium  symbiosum,  and 
Roseburia intestinalis), IV (Faecalibacterium prausnitzii, Clostridium orbiscindens and Dialiser invisus), 
IX and XIVb (Clostridium lactatifermentans) and, to a lesser extent, Streptococcus [43]. These results 
can be compared with the microbiota of ileum content taken at autopsy of three elderly persons from 
Japan  where  no  Bacteroidetetes,  but  many  Proteobacteria  (mostly  Klebsiella),  and  Firmicutes 
(dominated by Enterococcus, Lactobacillus and Streptococcus) were found [46].  
2.5. Large Intestine 
In colon and rectum, the mucosal microbiota of a middle-aged, healthy woman from Sweden was 
dominated by Firmicutes and Bacteroidetetes, the former represented by Clostridium clusters XIVa as 
defined  by  Collins  et  al.  [54]  (Eubacterium  halii,  Eubacterium  eligens,  Dorea  formicigenerans, 
Ruminococcus  lactaris,  Ruminococcus  gnavus,  Ruminococcus  torques,  Clostridium  symbiosum, 
Clostridium  boltei  and  Roseburia  intestinalis),  IV  (Faecalibacterium  prausnitzii  and  Clostridium 
orbiscindens),  IX  (Dialister  invisus),  XIVb  (Clostridium  lactatifermentans),  and  the  latter  by  
B.  vulgatus,  B.  thetaiotaomicron, Bacteroides  ovatus  and  B.  uniformis  [43].  Minor  proportions  of 
Verrucomicrobia,  Proteobacteria  (E.  coli,  Acinetobacter  johnsonii,  Sutterella  wadsworthensis  and 
Neisseria subflava) and Fusobacteria (Fusobacterium varium) were also present. These results can be 
compared with the microbiota of colonic and rectal content taken at autopsy of three elderly persons 
from Japan where Firmicutes strongly dominated, followed by Proteobacteria [46]. The former were 
represented by, for example, subgroups of Streptococcus salivarius and Butyrivibrio fibrisolvens, and 
the latter by subgroups of Klebsiella and Escherichia. The microbiota from sigmoid colon (biopsies) in 
nine 60-year-old volunteers, without clinical symptoms or medication, showed that a majority of the 
individuals had a heterogeneous flora, but in one person, 91% of the clones were related to E. coli [45]. 
The microbiota differed widely between individuals with regard to both composition and diversity. The 
largest number of clones identified close to the level of species for the whole cohort was related to  Nutrients 2011, 3  
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E.  coli,  Bacteroides  vulgatus  and  Ruminicoccus  torques.  Most  frequently  distributed  between  the 
volunteers were Bacteroides uniformis and B. vulgatus (7 out of 9 individuals). Bacteroides caccae, 
Bacteroides distasonis, Bacteroides putredinis, B. thetaiotaomicron and R. torques were found in 5 out 
of 9 individuals. Opportunistic pathogens found in more than one individual were Bacteroides fragilis, 
Escherichia coli and Bilophila wadsworthia, while Acinetobacter baumannii, Brachyspira aalborgi, 
Cardiobacterium hominis, Clostridium perfringens, Klebsiella pneumoniae and Veillonella parvula 
were found in single individuals [45]. In an early report, Hold et al [55] investigated the bacterial flora 
of colonic tissue from three elderly subjects: the flora was dominated by Bacteroides and Firmicutes, 
the latter related to either Clostridium coccoides (cluster XIVa as defined by Collins et al. [54]) or 
Clostridium leptum (cluster IV). 
Faeces from nine human, middle-aged subjects were dominated by Firmicutes and Bacteroidetes 
and with smaller proportions of Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia 
(sequences of 16S rRNA genes) [56]. Faeces from 156 individuals, 21–32 years old, confirmed the 
general strong domination of Firmicutes and Bacteroidetes, and the less pronounced proportions of 
Actinobacteria and Proteobacteria [51]. Examples of frequently occurring and dominating species are 
B. vulgatus, B. uniformis, B. thetaiotaomicron, Bacteroides ovatus, Bacteroides stercoris, B. caccae, 
B. putredinis, Bacteroides merdae, Bacteroides capillosus, B. fragilis and Parabacteroides distasonis 
among  the  Bacteroidetes,  and  amongst  the  Firmicutes:  Faecalibacterium  prausnitzii,  Eubacterium 
rectale, Eubacterium eligens, Eubacterium ventriosum, Eubacterium siraeum, Ruminococcus obeum, 
R.  torques,  Ruminococcus  gnavus,  Clostridium  leptum,  Clostridium  bolteae,  Clostridium  scindens, 
Coprococcus  eutactus,  Dorea  longicatena,  and  Anaerotruncus  colihominis  [51].  Other  frequently 
found Firmicutes in faeces are Blautia hansenii, Clostridium scindens, Clostridium asparagiforme, 
Clostridium  nexile,  Ruminococcus  gnavus,  Ruminococcus  lactaris,  Ruminococcus  bromii, 
Eubacterium  hallii,  Collinsella  aerofaciens,  Anaerotruncus  colihominis,  Butyrivibrio  crossotus, 
Coprococcus  eutactus,  Coprococcus  comes,  Holdemania  filiformis,  Subdoligranulum  variabile,  
Dorea  formicigenerans,  Dorea  longicatena,  Streptococcus  thermophilus,  Enterococcus  faecalis.  
Other  frequently  found  Bacteroidetes  are  Bacteroides  intestinalis,  Bacteroides  pectinophilus, 
Bacteroides finegoldii, Bacteroides eggerthii, Bacteroides capillosus, Bacteroides dorei, Bacteriodes 
xylanisolvens,  Parabacteroides  johnsonii,  Parabacteroides  merdae,  Roseburia  intestinalis  and 
Alistipes putredinis [40].  
2.6. Inflammation Driving Capacity 
For some chronic diseases, it has been suggested that the pathologic agent might be the disturbed 
microbiota  rather  than  a  single  organism  [57],  and  this  presumably  means  a  decreased  bacterial 
diversity and/or different degrees of overgrowth by more aggressive fractions of residential bacteria, 
i.e., bacteria inducing inflammatory responses by the immune system. A key question is then which 
bacteria are the most forceful ones in causing inflammation? Naturally, bacterial species known to be 
pathogenic or opportunistically pathogenic and genera including such species should be more prone to 
inducing inflammation. Species that are known to include pathogenic or opportunistically pathogenic 
strains and that also have been found as a substantial part of the gut microbiota of healthy individuals Nutrients 2011, 3  
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are E. coli and B. fragilis. Increased proportions of E. coli and B. fragilis have also been linked to 
inflammatory bowel diseases (IBD) [58–60].  
Gram-negative  bacteria  contain  lipopolysaccharide  (LPS)  as  the  major  constituent  in  the  outer 
leaflet  of  the  outer  cell  membrane.  LPS  contains  large  regions  of  variable  polysaccharide  and 
oligosaccharide regions and a relatively conserved lipid region (lipid A), which is the endotoxic and 
biologically active moiety responsible for septic shock. The interaction of LPS with macrophages 
results in the release of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1, and can lead to 
endotoxic shock, which is an often fatal outcome of sepsis. Although several receptors have been 
reported to bind to LPS, CD14 has been proven able to mediate these responses in vivo [61]. 
The  gram-reaction  of  different  taxa  relevant  for  the  GI  tract  is  a  factor  of  importance  as  
Gram-negative bacteria can be expected to contain LPS (Table 1). For example, both the facultatively 
aerobic  E.  coli and  the  strictly  anaerobic  B.  fragilis  contain  LPS,  but  the  chemical  structures  are 
somewhat different and the mammalian immune system reacts differently towards the different LPS 
types [62]. The endotoxic activity of LPS of B. fragilis is relatively low compared with LPS from  
E.  coli  and  other  Enterobacteriaceae  [63]  but,  nevertheless,  LPS  from  Bacteroides  is  a  potent 
stimulator  of  the  innate  immune  system  [64].  However,  the  immune  response  to  LPS  can  differ 
between LPS from different species of Bacteroides [64,65]. 
Gram-negatives that typically contaminate foods, and so are ingested on a more or less regular 
basis, sometimes in high quantities, are mostly Gammaproteobacteria, e.g., Enterobacteriaceaea and 
Pseudomonadaceae. However, different diet components can also affect the gut microbiota, e.g., a 
high-fat  diet  seems  to  increase  the  proportion  of  Gram-negatives  in  the  gut  but  also  increase  the 
leakage of LPS through the intestinal barrier [66]. A theory of how gram-negatives in the gut can 
affect fattening has been put forward by Cani et al. [66]. Diabetes type 2 and obesity are characterised 
by insulin resistance and low-grade inflammation, and Cani et al. [66] showed that LPS in the GI tract 
was the triggering factor for inflammation and obesity in a mouse model. A high-fat diet increased the 
LPS concentration in the blood, causing endotoxemia, which induced systemic inflammation, and in 
turn  initiated  a  process  leading  to  obesity  and  diabetes  in  the  mouse  [67].  It  is  not  known  why  
gram-negative components of the microbiota should be stimulated by a fat-rich diet, or why the barrier 
function  of  the  mucosa  should  decrease.  However,  one  speculation  could  be  that  a  fat-rich  diet 
increases the amount of bile in the gut, and bile has strong antimicrobial effects, but some taxa have 
higher resistance against bile than others, e.g., Enterobacteriaceae and Bacteroides are known for their 
comparably high bile resistance. Furthermore, bile is a powerful detergent which might have effects on 
the permeability of the mucosa and mediate an increased leakage of LPS. 
It should be stressed that it is not only gram-negatives and LPS that can induce inflammation; other 
cell components and metabolites can be involved, and there are also several gram-positive pathogenic 
and opportunistic pathogenic bacteria that can induce inflammation [68]. One example of the latter is 
Enterococcus, which is frequently found as a contaminant in foods.  
An attempt to look for correlation between systemic inflammation and faecal microbiota showed 
that about 9% of the total variability of the microbiota was related to the pro-inflammatory cytokines 
IL-6  and  IL-8  [69].  All  taxa  that  showed  a  slightly  positive  correlation  with  either  IL-6  or  IL-8 
belonged to the phylum Proteobacteria [69].  Nutrients 2011, 3  
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It  should  be  borne  in  mind  that  different  taxa  of  the  microbiota  in  combination  can  enhance 
pathogenic effects. This can be demonstrated in animal models, e.g., in rat models for intra-abdominal 
sepsis that cause a two-phase disease process consistent with intra-abdominal sepsis in humans, it has 
been shown that a combination of obligate anaerobes such as B. fragilis or Fusobacterium varium and 
facultative aerobes such as E. coli or Enterococcus faecalis cause early peritonitis and mortality, and 
abscess development [70]. In this case, E. coli was necessary for the mortality, and a combination of  
E. coli and B. fragilis was needed for the abscess development [70,71]. Neither E. coli nor B. fragilis 
alone provoked abscess formation. Results along the same lines were found in mice infected with  
E. coli and B. fragilis in the peritoneal cavity. The co-infection showed an increase in TNF-alpha 
production in the peritoneal tissues compared with infection by B. fragilis alone [72]. KC mRNA in 
peritoneal tissues was up-regulated after infection with B. fragilis which was paralleled by increased 
KC protein secretion and, after intraperitoneal co-infection with E. coli and B. fragilis, a synergistic 
increase in the expression of KC could be noted [72]. B. fragilis inhibits the phagocytic killing of  
E. coli [71,73] while E. coli inhibits phagocytosis and intracellular killing of B. fragilis [74]. Also,  
B. fragilis seems to suppress the E. coli associated LPS-induced human endothelial cell adhesiveness 
for neutrophils [75]. 
2.7. Bacterial Neutralisation of Inflammation 
There are fractions of the resident GI microbiota that are less prone to inducing inflammation, and 
there  may  even  be  certain  taxa  with  the  ability  to  counteract  inflammation.  This  seemingly 
inflammation-suppressing effect can be a result of different actions. The inflammation-suppressing 
fractions of the microbiota may: (i) counteract some of the inflammation-aggravating bacteria, which 
will decrease the inflammatory tone of the system; (ii) improve the barrier effect of the GI mucosa, 
which allows less inflammation-inducing components in the lumen to translocate out into the body; 
(iii) more directly interact with inflammation-driving components of the immune system. All three 
actions may be at work simultaneously.  
When the systemic inflammatory tone measured as IL-6 and IL-8 was compared, some members of 
the Clostridium cluster XIVa (as defined by Collins et al. [54]) were inversely correlated with systemic 
inflammation  [69].  It  has  also  been  shown  that  a  low  proportion  of  Faecalibacterium  prausnitzii 
(family Ruminococcaceae; Clostridium cluster IV or the Clostridium leptum group in older vocabulary) 
on resected ileal mucosa from Crohn’s disease patients is associated with endoscopic recurrence [76]. 
Furthermore,  F.  prausnitzii  was  proved  to  possess  anti-inflammatory  effects  in  model  systems: 
secreted metabolites blocked NF-B activation and IL-8 secretion in Caco-2 cells, and stimulation of 
peripheral blood mononuclear cells by F. prausnitzii led to an anti-inflammatory IL10/IL12 ratio. Oral 
administration of F. prausnitzii also reduced the severity of 2,4,6-trinitrobenzenesulphonic acid colitis 
in mice [76].  
The  currently  most  studied  inflammation-suppressing  taxa  of  the  GI  microbiota  are  certain 
species/strains of Lactobacillus and Bifidobacterium, and those are also the fractions that are supported 
by administering probiotics (living microorganisms that upon ingestion exert health-beneficial effects), 
or  certain  dietary  fibres  that  selectively  stimulate  resident  Lactobacillus  and  Bifidobacterium 
(prebiotics). Intestinal exposure to specific bacterial strains may either suppress an undesired immune Nutrients 2011, 3  
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response,  for  example  allergic  and  autoimmune  reactions,  or  act  in  a  more  generalised  immune 
stimulatory way, associated with adjuvanticity and increased intestinal non-specific IgA secretion [77]. 
3. Probiotics for Humans 
3.1. Species Used as Probiotics 
Originally, probiotics meant organisms or substances that contribute to intestinal microbial balance, 
in contrast to antibiotics that counteract microbial activity [78]. However a currently widely accepted 
definition is that ―probiotics are live microorganisms which when administrated in adequate amounts 
confer a health benefit on the host‖ [79]. In other words, the designation ―probiotics‖ refers to a 
function, and not to a taxonomic unit. Humans have always ingested bacteria unintentionally together 
with food. The bacteria could be adverse, but they could also be harmless ―dietary bacteria‖ when 
fermented foods were consumed. In particular, lactic acid fermented foods such as yoghurt, cheese, 
sauerkraut, salted gherkins, olives and capers can contain high amounts of live bacteria and often 
bacteria of the same Lactobacillus species that are now used for probiotics. Yoghurt was launched in 
Paris 1906 with reference to the theories of Metchnikoff [80]. In search of strains with better resistance 
to the low pH of the stomach and the digestive juices of duodenum, Lactobacillus acidophilus was 
launched in USA in the 1930s, and in Japan during the same period, Lactobacillus casei (should 
probably be L. paracasei) started to be used as probiotics.  
Popular probiotic species used commercially include L. paracasei, L. rhamnosus, L. acidophilus,  
L. johnsonii, L. fermentum, L. reuteri, L. plantarum, Bifidobacterium longum and Bifidobacterium 
animalis.  However,  the  phylogenetic  differences  are  extremely  wide  between  Lactobacillus  and 
Bifidobacterium  as  they  belong  to  different  phyla,  but  there  are  also  great  differences  between 
Lactobacillus species such as L. acidophilus, L. fermentum, L. reuteri and L. plantarum. Even within 
different strains of the same species, the genomic differences can be considerable, which has been 
clearly demonstrated for L. paracasei [81]. Consequently, with major genetic differences between 
different probiotics it is also to be expected that the human body will respond differently to different 
probiotics.  This  is  something  that  is  not  always  taken  into  account  and  it  is  often  neglected  in 
discussions of probiotic effects. Furthermore, it should be stressed that the bacterial species includes 
considerably genomic heterogenicity. The consensus definition of a bacterial species is that two strains 
are of the same species if they have a relative ratio of binding of 70% DNA:DNA homology of the 
genomes at optimal and stringent re-association temperatures (optimal temperature, 25 °C  below the 
melting  point  of  the  DNA;  stringent  temperature,  15  °C   below  the  melting  point  of  the  DNA). 
Consequently,  the  body  can  react  very  differently  to  different  strains  of  the  same  species. 
Unfortunately strain identity is not always given in studies of probiotics administered to humans,  
e.g., in a failed attempt to improve the clinical outfall in acute pancreatitis where a mixture of strains 
were given to the patients [82]. The species identity is given in the paper, but no labels on the strains 
are given. The same is true for a successful attempt to treat acute pancreatitis with a single strain of  
L. plantarum [83]; no strain identity was given. Examples of different human trials with probiotic 
treatment, and with use of different species/strains are summarised in Table 2.  
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Table 2. Examples of human trials with probiotics and the strains used for tretament. 
Category of 
subjects 
Strains  Major symptom 
affected 
Systemic marker affected  Ref. 
Healthy subjects  L. salivarius CECT5713  -  NK-cells, monocytes, IgM, IgA, 
IgG, IL-10 
[84] 
  L. casei Shirota  -  NK-cells  [85] 
  L. paracasei Lpc-37, 
L. acidophilus 74-2, 
B. animalis subsp. lactis 
DGCC 420 
-  CD57+, phagocytic activity 
oxidative burst  
[86] 
  L. acidophilus 74-2, 
B. animalis subsp. lactis 
DGCC 420 
-  phagocytic activity  [87] 
  L. rhamnosus GG  -  Receptors CR1, CR3, FcγRI, IgαR  [88] 
  L. plantarum WCSF1  -  Occluding, ZO-1  [89] 
Metabolic syndrome 
and low-grade 
inflammation 
L. acidophilus 145, 
B. longum 913 
-  HDL-cholesterol  [90] 
  L. helveticus -, 
S. cerevisiae - 
Blood pressure  -  [91] 
  L. plantarum 299v  -  total cholesterol,  
LDL-cholesterol, fibrinogen 
[92] 
  L. plantarum 299v  Systolic blood 
pressure 
leptin, fibrinogen,  
F2-isoprostanes, IL-6 
[93] 
  B. lactis HN019  -  CD3+, CD4+, CD25+, CD56+, 
phagocytic activity, tumoricidal 
activity of NK cells 
[94] 
Non-alcoholic fatty 
liver disease 
(NAFLD) 
Mixture 
(1)  -  alanine-aminotransferase (ALAT), 
γ-glutamyl-transpeptidase,  
4-hydroxynonenal, TNF-α 
[95] 
  VSL#3 
(2)  -  S-nitrosothiols, malondialdehyde 
(MDA), 4-hydroxynonenal 
[96] 
Alcohol-related liver 
injury 
B. bifidum -, 
L. plantarum 8PA3 
-  ALAT, aspartate-aminotransferase 
(ASAT), gamma glutamyl 
transpeptidase, lactate 
dehydrogenase, bilirubin 
[97] 
  L. casei Shirota  -  neutrophil phagocytic activity 
TLR4 
[98] 
Fibrosis, cirrhosis, 
liver transplantations 
and minimal hepatic 
encephalopathy 
(MHE) 
P. pentoseceus 5-33:3, 
L. mesenteroides 32-77:1, 
L. paracasei 19, 
L. plantarum 2592 
Child-Turcotte-Pugh 
score 
ammonia, endotoxin, bilirubin, 
ALAT, albumin, prothrombin 
activity 
[99] 
  L. acidophilus -  Clinical status  ammonia  [100, 
101] 
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Table 2. Cont. 
  S. thermophilus-, 
L. bulgaricus -, 
L. acidophilus -, 
bifidobacteria -,  
L. casei - 
MHE reversal  -  [102] 
  L. plantarum 299  Incidence of 
postoperative 
infections 
-  [103] 
  P.pentosaceus 5-33:3, 
L. mesenteroides 77:1, 
L. paracasei F19, 
L. plantarum 2362 
Incidence of 
postoperative 
infections 
-  [104] 
Acute pancreatitis  ―Ecologic 641‖ 
(3)  - 
(4)  -  [82] 
Acute pancreatitis  L. plantarum -  Clinical outcome  -  [83] 
Critically ill patients  L. plantarum 299v  -  IL-6, intestinal translocation  [105] 
  L. plantarum 299v  -  intestinal translocation, IL-10 
white blood cell count, lactate  
[106] 
  VSL#3  -  IgA, IgG  [107] 
Allergy; infants   L. acidophilus  
LAVRI-A1 
-  -  [108] 
  L. rhamnosus GG  Atopic eczema  -  [109] 
  B. lactis Bb-12  SCORAD score  soluble CD4, eosinophilic  
protein X 
[110] 
  L. rhamnosus GG  SCORAD   soluble CD4, eosinophilic  
protein X 
[110] 
  L. acidophilus NCFM, 
B. lactis Bl-04 
Nasal symptoms  IgA  [111] 
  L. rhamnosus GG  -  IgA, alpha1-antitrypsin  [112] 
  mixture 
(5)  -  IgA  [112] 
  L. gasseri CECT5714, 
L. coryniformis 
CECT5711 
-  IgE, IgA, CD4(+)CD25(+) 
T regulatory cells, NK-cells 
[113] 
  B. lactis Bb12  Body weight  Calprotectin, IgA  [114] 
Allergy; adults  L.paracasei Lpc-37, 
L. acidophilus 74-2, 
B. animalis subsp. lactis 
DGCC 420 
-  CD4(+)CD54(+)  [86] 
  L. rhamnosus GG  -  Receptors CR1, CR3, FcγRI, IgαR  [88] 
Crohn’s disease  L. rhamnosus GG  None 
(6)  -  [115] 
  L. rhamnosus GG  None  -  [116] 
  L. rhamnosus GG  None  -  [117] 
  L. rhamnosus GG  Clinical outcome  -  [118] 
  L. rhamnosus GG  Clinical activity  Intestinal permeability  [119] 
  L. johnsonii LA1  None  -  [120] 
  L. johnsonii LA1  None  -  [121] Nutrients 2011, 3  
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Ileal pouchitis, 
ulcerative colitis and 
colorectal cancer 
VSL#3   Disease activity  CD4+CD25
high cells, CD4+  
LAP+ cells, IL-1β mRNA,  
Foxp3 mRNA 
[122] 
  VSL#3  Disease activity 
index, remisson 
-  [123] 
  VSL#3  Remission  -  [124] 
  VSL#3  Disease activity 
index, inflammatory 
bowel disease 
questionnaire, 
remission  
-  [125] 
  BIO-THREE 
(7)  Clinical symptoms, 
endoscopic findings 
-  [126] 
  E. coli Nissle 1917  Clinical symptoms  -  [127] 
  L. rhamnosus GR1, 
L. reuteri RC-14 
-  CD4+CD25
high cells, IL-12,  
TNF-α/IL-12-producing 
monocytes, DCs 
[128] 
  L. rhamnosus GG  Remission  -  [129] 
  B. breve Yakult,  
B. bifidum Yakult, 
L. acidophilus - 
Clinical activity 
index, endoscopic 
activity index 
-  [130] 
  Bifidobacterium -, 
Lactobacillus -, 
Enterococcus - 
Flare-ups  NF-κB, TNF-α, IL-1β, IL-10  [131] 
  Bifidobacterium -  Postoperative septic 
complications 
SIgA, IgG, IgM, IgA, IL-6,  
C-reactive protein (CRP) 
[132] 
Radiation-induced 
enteritis 
VSL#3  Diarrhea, bowel 
movements 
-  [133] 
  L. rhamnosus -  Bowel movements, 
stool consistency 
-  [134] 
  L. rhamnosus GG  Diarrhea, abdominal 
discomfort 
-  [135] 
  L. acidophilus -  Diarrhea, flatulence  -  [136] 
  L. casei DN-114 001  Stool consistency  -  [137] 
(1) Mixture containing L. acidophilus, L. bifidus, L. rhamnosus, L. plantarum, L. salivarius, L. bulgaricus, 
L. lactis, L. casei, and L. breve; no strain labels are given in the paper; 
(2) VSL#3 is a mixture of L. casei, 
L. plantarum, L. acidophilus, L. delbrueckii subsp. bulgaricus, Bifidobacterium longum, B. breve, B. infantis 
and ―Streptococcus salivarius subsp. thermophilus‖; no strain labels are given in the paper; 
(3) ―Ecologic 641‖ 
is a mixture containing Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius, Lactococcus 
lactis, Bifidobacterium bifidum, and Bifidobacterium lactis; no species labels are given in the paper; 
(4) No 
effect  on  occurrence  of  infectious  complications  and  increased  risk  of  mortality; 
(5)  Mixture  containing 
L. rhamnosus GG ATCC 53103, L. rhamnosus LC705, B. breve Bbi99, and Propionibacterium freudenreichii 
subsp. shermanii JS 2; 
(6) ―None‖ is indicating that no significant effects on symptoms or clinical outcome 
could be noted; 
(7) BIO-THREE is a mixture of Streptococcus faecalis T-110, Clostridium butyricum TO-A 
and Bacillus mesentericus TO-A. Nutrients 2011, 3  
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3.2. Immune Modulation  
3.2.1. T Regulatory Cells: A Key Factor in Several Dysfunctions 
Modification  of  immune  responses  in  humans  is  an  important  potential  mechanism  by  which 
probiotic bacteria may confer health benefits. Regulatory T cells are involved in the regulation of 
immune response, maintaining immunological self-tolerance and immune homeostasis, and the control 
of autoimmunity and cancer surveillance. Consequently, T cells play a key role in autoimmunity, 
allergy,  cancer,  infectious  disease,  and  the  induction  of  transplantation  tolerance.  T  cells  are 
characterised by the expression of FoxP3 and additional characteristics include constitutive expression 
of  IL-2  receptor  alpha  (CD25),  the  T  cell  activation  marker  CTLA-4  and  the cell  survival  factor  
GITR [138,139]. 
The capacity of probiotic bacteria to affect regulatory T cells has only been evaluated in a few 
human trials. How the regulatory T cells function in relation to the subsequent development of an early 
allergic phenotype, after a probiotic supplementation to infants during their first 6 months of life, has 
been evaluated but it did not appear to modify the regulatory pathways or the risk of developing atopic 
dermatitis  [108].  However,  in  patients  with  ulcerative  colitis,  different  results  have  been  found.  
In humans, CD4+CD25+ T lymphocytes with regulatory activity reside in the population of CD25+ 
T lymphocytes with a high expression of CD25 on the cell surface (CD4+CD25
high) [140]. Patients 
suffering  from  inflammatory  bowel  disease  have  an  increased  number  of  lamina  propria 
CD4+CD25
high cells in inflamed tissue compared with control patients, although it is not sufficient to 
dampen  inflammation  [141].  Patients  undergoing  ileal  pouch  anal  anastomosis  for  UC  were 
randomised in an open-label study of a probiotic mixture of different strains, VSL#3, for 12 months.  
VSL#3-treated patients showed a significant reduction in pouchitis disease activity index score and a 
significant increase in the percentage of infiltrating CD4+CD25
high and CD4+ LAP-positive cells to 
the lamina propria, compared with baseline values. Tissue samples revealed a significant reduction in  
IL-1β  mRNA  expressions,  and  a  significant  increase  in  Foxp3  mRNA  expression.  During  mild 
inflammation, this expansion of regulatory cells seems to be adequate to dampen inflammation leading 
to pouchitis [122]. 
In an open-label study, 20 patients with IBD (15 with Crohn’s disease and 5 with ulcerative colitis) 
and 20 healthy subjects consumed probiotic yoghurt containing L. rhamnosus GR-1 and L. reuteri  
RC-14 for 30 days. The aim of the study was not to cure IBD or to study the clinical outcomes of the 
treatment, but to determine whether the consumption induced an anti-inflammatory environment in the 
patients. After consumption, a significantly increased proportion of CD4+CD25
high cells were found in 
the peripheral blood of IBD patients. Decreased concentrations of IL-12 in serum as well as decreased 
percentages of TNF-α- and IL-12-producing monocytes and myeloid dendritic cells were also detected. 
Furthermore it was observed that the production of TNF-α and IL-12 correlated to the number of 
CD4+CD25
high  cells  in  IBD  patients.  Even  if  the  changes  of  immunological  parameters  found  in 
healthy subjects were fewer and more moderate, they were in line with those found in the patients. To 
verify the influence of the probiotic bacteria, the treatment scheme was repeated with a subpopulation 
of the same patients after a washout period, using unsupplemented yoghurt. After this consumption,  Nutrients 2011, 3  
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no  significant  changes  could  be  seen  in  the  percentage  of  CD4+CD25
high  cells  or  percentages  of  
TNF-α- and IL-12-producing cells [128]. 
Systemic IgA and IgG concentrations have been shown to be increased in intensive care patients 
suffering from multiple organ dysfunction syndrome given the mixture of probiotic strains, VSL#3, for 
7 days [107]. Through production of TGF-β by regulatory T cells in the mucosa, the B cell function 
can  be  modulated  and  antibody  class  switching  may  be  determined  by  stimulating  switching  to 
IgA [142,143]. 
3.2.2. Healthy and Allergic Adults 
When 40 healthy adults were given Lactobacillus salivarius for four weeks, the concentration of 
NK cells and monocytes increased, together with the plasma levels of immunoglobulins M, A and G, 
and the regulatory cytokine IL-10 [84]. Also, ingestion of Lactobacillus casei strain Shirota for three 
weeks  increased  the  activity  of  the  NK  cells  [85].  The  relative  risk  for  infection  increases  with 
decreasing NK cell activity [144]. The increase in NK cells induced by probiotics could also stimulate 
a Th1 phenotype with positive effects on allergic patients with Th2 predominance [113]. 
A mixture of L. paracasei, L. acidophilus and B. animalis subsp. lactis was given for eight weeks to 
adults with atopic dermatitis (AD) and to healthy controls [86]. Major lymphocyte subsets were not 
affected  but  the  expression  of  CD57+  (mainly  expressed  on  the  natural  killer  cells)  increased 
significantly in healthy subjects after probiotic intake but was not changed in the AD patients, whereas 
the expression of CD4(+)CD54(+) decreased significantly in the patients and remained unaffected  
in  the  healthy  subjects.  ICAM-1  (CD54+)  is  an  adhesion  molecule  that  is  up-regulated  during 
inflammation, as indicated in the atopic patients. After the probiotic treatment, the phagocytic activity 
of  monocytes  and  granulocytes  and  oxidative  burst  activity  was  also  increased  in  the  healthy  
controls [86]. The elevated expression of CD57+ in the healthy subjects indicates a stimulation of the 
immune system, which may decrease the theoretical risk of infections. Increased phagocytic activity in 
healthy subjects was also found after administration of L. acidophilus and B. animalis subsp. lactis, 
where the probiotics were able to elevate the percentages of granulocytes and monocytes showing 
phagocytic activity, but in this case the oxidative burst activity remained unaffected [87]. 
L. rhamnosus strain GG prevented an increased expression of phagocytosis receptors (CR1, CR3, 
FcγRI  and  IgαR)  in  milk-hypersensitive  subjects,  indicating  that  the  probiotic  bacteria  had  the 
potential  to  down-regulate  the  inflammatory  response  induced  by  milk  [88].  In  the  control  group 
consisting  of  healthy  subjects,  L.  rhamnosus  GG  had  an  immune-stimulatory  effect  observed  as 
increased  receptor  expression  after  milk  consumption  containing  L.  rhamnosus  GG.  It  was 
hypothesised  that  microbial  stimulation  by  probiotic  bacteria  may  modulate  the  immune  response 
differently in healthy individuals, where it appears to stimulate a nonspecific immune response to 
pathogens, while in hypersensitive subjects it down-regulated the inflammatory response [88]. It can 
be  speculated  whether  the  underlying  mechanism  is  associated  with  an  existing  difference  in 
composition  of  the  resident  microbiota.  Depending  on  the  health  status  of  the  individual,  an 
aggravating  or  a  suppressing  microbiota  could  be  present.  The  interaction  between  various  
immune-competent cells may generate divergent immune-regulatory signals [86]. 
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3.2.3. Allergic Children 
The composition of the intestinal microbiota has been implicated in the development of atopic 
diseases, and in a large prospective birth cohort study the intestinal microbiota of nearly 1000 infants 
aged one month was examined. The infants were monitored for subsequent development of atopic 
manifestations and/or sensitisation within the first two years of life. The study demonstrated that the 
presence of E. coli was associated with a higher risk of developing eczema and this risk was increased 
with increasing numbers of E. coli [145]. Furthermore, colonisation with Clostridium difficile was 
associated with a higher risk of developing eczema, recurrent wheeze and allergic sensitisation, and 
also with a higher risk of a diagnosis of atopic dermatitis [145]. The results indicate that differences in 
gut  microbiota  composition  precede  the  development  of  atopy  and  since  different  species  were 
associated  with  different  outcomes,  the  underlying  mechanisms  explaining  these  associations  may  
vary [145]. It has also been seen that low bacterial diversity found in one-week-old infants more 
frequently gave rise to the diagnosis atopic eczema after 18 months than those with high bacterial 
diversity [146]. 
An allergic reaction is the result of an inappropriate immune response triggering inflammation, and 
several studies have been performed to investigate potential immunoregulatory properties of probiotics 
in children. Specific probiotic strains have been demonstrated to be effective in prevention of early 
atopic disease in children at high risk [109], but also as curative of atopic eczema with improvement in 
skin condition and reductions in serum concentration of soluble CD4 and eosinophilic protein X in 
urine  [110],  suggesting  mitigated  allergic  inflammation  both  locally  and  systemically.  Allergy 
symptoms  from  birch  pollen  in  children  were  assessed  by  administration  of  L.  acidophilus  and  
B. lactis. The combined probiotic strains prevented the pollen-induced infiltration of eosinophils into 
the nasal mucosa, and a trend for reduced nasal symptoms was indicated [111]. Consequently, the 
results  showed  that  probiotics  taken  orally  affect  the  inflammatory  processes  involved  in  airway 
allergies. The faecal levels of bifidobacteria, clostridia and Bacteroides were reduced at the peak of the 
birch pollen season. Even faecal IgA was increased in the placebo group during the pollen season, but 
this increase was prevented by the probiotics [111]. 
Inflammation  in  the  gut  has  been  shown  in  children  with  atopic  eczema/dermatitis  syndrome 
(AEDS) and food allergy [147,148]. In a randomised double-blinded manner and concomitant with 
elimination  diet,  230  infants  with  AEDS  and  suspected  cow’s  milk  allergy  were  given  either  
L. rhamnosus GG, or a mixture of four probiotic strains (L. rhamnosus GG, L. rhamnosus LC705, 
Bifidobacterium breve Bbi99, and Propionibacterium freudenreichii subsp. shermanii) for four weeks. 
IgA levels tended to be higher in the probiotic groups than in the placebo group, and alpha1-antitrypsin 
decreased by administration of L. rhamnosus GG, which may indicate that L. rhamnosus GG may 
alleviate intestinal inflammation in infants with AEDS and cow's milk allergy [112]. 
Compared  to  a  conventional  yogurt,  a  probiotic  product  containing  Lactobacillus  gasseri  and 
Lactobacillus coryniformis enhanced innate and specific immune parameters in allergic children by 
decreasing the level of IgE in plasma (IgE rise in response to allergens in predisposed atopic subjects), 
increasing CD4(+)/CD25(+) T regulatory cells as well as natural killer cells [113]. The decrease in IgE 
was  accompanied  by  a  significant  increase  in  mucosal  IgA  [113],  which  may  be  caused  by  the Nutrients 2011, 3  
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regulatory  T  cells.  The  mucosal  immune  system  contains  T  cells  capable  of  positively  regulating  
IgA-specific isotype differentiation, thereby allowing for efficient generation of IgA-secreting B cells. 
Preterm infants are prone to abnormal bacterial colonisation of the intestine with ensuing adverse 
health  effects.  Oral  application  of  B.  lactis  strain  Bb12  for  21  days  was  used  in  a  double  blind, 
placebo-controlled randomised clinical study performed on preterm infants (<37 gestation weeks). 
In antibiotic-treated  infants,  i.e.,  infants  that  have  been  subjected  to  standard  antibiotic  therapy, 
probiotic supplementation resulted in a higher body weight compared with placebo. Faecal calprotectin 
(used as a marker of gastrointestinal inflammation) was lower in the probiotic group, while faecal IgA 
was higher in this group compared with the placebo group [114]. Probiotics can increase levels of  
IgA-producing cells in the lamina propria and promote IgA secretion into the luminal mucous layer. 
3.3. Metabolic Syndrome and Low-Grade Inflammation 
The  metabolic  syndrome  is  a  combination  of  disorders  that  increase  the  risk  of  developing 
cardiovascular disease and diabetes. Factors contributing to the syndrome are increased triglycerides in 
the blood, decreased HDL cholesterol in the blood, increased blood pressure, increasing fasting plasma 
glucose  and  central  obesity.  The  metabolic  syndrome  is  characterised  by  a  systemic,  low-grade 
inflammation. LPS leaking out into the body from the gram-negative part of the intestinal microbiota 
may be the triggering factor for the low-grade inflammation, so probiotics may be a means to improve 
the gut-barrier and suppress gram-negatives in the GI channel. The ability of many Lactobacillus 
strains to counteract, for example, E. coli is well known, and the ability of certain probiotic strains,  
for  example,  L.  plantarum  299v,  to  mitigate  bacterial  translocation  has  been  proved  in  animal  
models but it has also been tentatively shown in humans [105,106]. Furthermore it has been shown in 
healthy humans that L. plantarum WCSF1 increased the relocation of occludin and ZO-1 into the tight 
junction area between duodenal epithelial cells [89]. The ability of different Lactobacillus strains to 
improve  the  barrier  effect  of  the  mucosa  and  suggested  mechanisms  for  this  has  recently  been 
reviewed by Ahrné  and Johansson Hagslä tt [149]. 
In connection to the metabolic syndrome, it must also be mentioned that the GI microbiota of mice 
seems to be essential for the processing of dietary polysaccharides [150], and in humans it has been 
shown that the relative proportion of Bacteroidetes in comparison with Firmicutes is lower in obese 
individuals than in lean ones; the increased abundance of Bacteroidetes correlated with percentage loss 
of  body  weight  [151].  Furthermore,  the  proportion  of  Bacteroidetes  increased  with  time  in  obese 
individuals put on a low-calorie diet [151]. To certain extent this contradicts the suggestion that the 
LPS should be the trigger of the metabolic syndrome, as members of the phylum Firmicuses do not 
contain  LPS.  On  the  other  hand,  the  genus  Lactobacillus  belongs  to  Firmicutes,  and  probiotic 
lactobacilli have been accused of contributing to exaggerated weight-gain [152,153]. The accusation 
has been turned down most convincingly by Ehrlich [154] and Delzenne and Reid [155]. It must be 
borne in mind that the phylum Firmicutes is a taxon on a high taxonomic hierarchy and includes an 
extremely wide genomic variation of bacteria, and that loss of weight in mammals also can be an 
endpoint for ill-health. 
Disorders  in  the  lipid  metabolism  can  cause  hypertension,  and  hypertension  is  often  linked  to 
hypercholesterolemia.  Yoghurt  supplemented  with  L.  acidophilus  and  B.  longum  increased  HDL Nutrients 2011, 3  
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cholesterol  [90],  and  a  sour-milk  fermented  with  Lactobacillus  helveticus  together  with  the  yeast 
Saccharomyces  cerevisiae  decreased  the  blood  pressure  in  elderly  hypertensive  subjects  [91]. 
Furthermore,  in  a  small  but  randomised,  placebo-controlled  and  double  blind  study  on  men  with 
slightly elevated cholesterol levels, it was shown that the concentrations of total cholesterol and of 
LDL cholesterol were decreased after consumption of L. plantarum 299v in a beverage containing 
rosehip and a small quantity of oats (placebo was a similar beverage without probiotics [92]). The fall 
in cholesterol level was small but statistically significant. Interestingly, the fibrinogen level in serum 
also decreased (P < 0.001), representing a reduction of 13.5% [92]. Fibrinogen is an acute phase 
protein, a good marker for systemic inflammation and it is also an independent risk factor for coronary 
artery disease [156]. 
Smokers are at increased risk of developing systemic inflammation since tobacco smoke triggers 
the production of free radicals [157,158]. A controlled, randomised, double-blind trial of smokers 
consuming L. plantarum strain 299v for 6 weeks affected systemic parameters, i.e., the systolic blood 
pressure  decreased,  and  so  did  the  concentration  in  blood  of  leptin,  fibrinogen,  F2-isoprostanes  
(marker for oxidative stress) and the proinflammatory cytokine IL-6 [93]. 
The ageing process is known to adversely affect the immune system [159,160]. An association 
between the inflammatory status and the presence of chronic diseases in elderly has been suggested, 
but also the interaction of an altered microbiota could contribute to maintaining a low-grade, systemic 
inflammation [161]. In a recent pilot study of elderly persons, the intestinal load of lactobacilli was 
linked to the count of white blood cells, blood glucose and content of oxidised low-density lipoprotein 
(ox-LDL), all risk markers in the pathogenesis of inflammation, metabolic syndrome and cardiovascular 
disease [162]. 
Thirty healthy elderly volunteers were given a dietary supplement of a probiotic drink containing 
Bifidobacterium lactis for three weeks. The proportion of mononuclear leukocytes staining positively 
for CD3+ (T lymphocytes), CD4+ (MHC II–restricted T cells), CD25+, and CD56+ (NK cells) as well 
as the phagocytic capacity of mononuclear and polymorphonuclear phagocytes and the tumoricidal 
activity of NK cells increased significantly in blood after the probiotic administration. The greatest 
relative increase in immune function occurred in individuals with poor immune responses before the 
intervention [94]. 
3.4. Liver Injury 
3.4.1. Liver Homeostasis 
The gut and the liver are closely connected. A well functioning link between the gut and the liver is 
dependent on both an intact intestine and a liver in balance with respect to immunologic response and 
metabolism of endogenous and exogenous compounds [163,95]. The intestinal mucosa functions as 
the  local  defence  barrier  that  helps  to  prevent  the  invasion  and  systemic  spread  of  bacteria  and 
endotoxins, which are mostly LPS from the cell walls of gram-negative bacteria. However, under 
certain conditions, intestinal barrier function can be impaired or overwhelmed, allowing bacteria and 
endotoxins  within  the  GI  tract  to  reach  systemic  organs  and  tissues,  a  process  termed  bacterial 
translocation [164]. On the other hand, there is evidence that portal vein endotoxaemia of gut origin in Nutrients 2011, 3  
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minute  amounts is a normal  physiological phenomenon [165,166]. During normal conditions, this  
low-grade endotoxaemia of gut origin is rapidly cleared by the cells of the reticuloendothelial system 
of the liver [167,168]. Through the portal blood flow draining the GI tract, intestinal bacteria and 
bacterial  products,  such  as  LPS,  reach  the  liver  and  the  parenchymal  cells  (hepatocytes)  and  the  
non-parenchymal cells, encompassing endothelial cells, Kupffer cells, hepatic stellate cells and Pit 
cells  (liver-specific  natural  killer  cells),  help  to  sustain  normal  physiology  and  homeostasis,  and 
participate in systemic, as well as in local inflammation and immune response [169]. Some examples 
of  bacterial  species  that  are  likely  to  have  positive  effects  on  the  ecology  of  the  GI  channel 
(successfully used as probiotics), and some other examples of species that now and then can be found 
as significant parts of resident human microbiota and known for possessing pathogenic potential are 
given in Figure 1.  
Figure 1. Some examples of bacterial species that are likely to have positive effects on the 
ecology of the gastro-intestinal (GI) channel (certain strains successfully used as probiotics), 
and some other examples of species that can occasionally be found as significant parts of 
resident human microbiota, and are known to possess pathogenic potential (involvement in 
human infections). The aggressive potential of the adverse species can lead to a weakened 
barrier effect of the mucosa and leakage of bacterial components that end up in the liver, 
which will give an inflammatory response. Direct gene identification has shown that the 
examples of adverse bacteria described form a substantial part of the microbiota in the 
gastro-intestinal tract of individuals without diagnosed disease [43,45,47,49]. 
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The aggressive potential of the adverse examples can weaken the barrier effect of the mucosa and 
allow leakage of bacterial components out into the body. These components will end up in the liver, 
and the liver will respond with inflammation. Some components of the microbiota will, in contrast, 
and by different conceivable mechanisms, decrease the leakage of proinflammatory components from 
the gut, effects so far only proved for certain probiotic strains of the given species.  
The liver is an important site for bacterial phagocytosis and clearance as it contains the largest 
population  of  tissue  macrophages.  Activated Kupffer  cells,  the  resident  macrophages  of  the  liver, 
exposed  to  pro-inflammatory  mediators  such  as  LPS  or  other  bacterial  products,  are  the  major  
source  of  inflammatory  mediators  including  pro-inflammatory  cytokines,  chemokines  and  reactive 
oxygen/nitrogen species, which contribute to liver injury [170]. However, bacterial particles entering 
the circulation can also be cleared and detoxified to some extent in the serum by serum proteins such 
as LPS-binding protein, bactericidal/permeability-increasing protein, and high-density lipoprotein [171]. 
Through pattern recognition receptors, including Toll-like receptors (TLRs), the innate immune system 
recognises conserved PAMPs [172]. The healthy liver shows low mRNA levels of TLRs such as 
TLR1, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9 and TLR10, implying a high tolerance of the liver to 
TLR ligands from the GI microbiota, to which it is constantly exposed. Signalling through TLRs plays 
a major role in the physiology and pathophysiology of the liver [173].  
LPS,  membrane components of gram-negative bacteria, are potent activators of innate immune 
responses through their binding to the TLR4 complex. TLR4 is expressed by Kupffer cells, hepatic 
stellate cells, hepatocytes, biliary epithelial cells, sinusoidal endothelial cells and hepatic dendritic 
cells, and are consequently responsive to LPS [173]. There is a positive correlation between liver 
dysfunction  and  the  occurrence  of  bacterial  translocation,  and  the  clearance  of  LPS  from  the 
circulation is decreased in states of hepatic dysfunction, such as cirrhosis [174]. 
3.4.2. Fibrosis, Cirrhosis and Minimal Hepatic Encephalopathy 
Chronic liver injury is associated with the development of fibrosis, since repeated and continuous 
hepatocellular  damage  leads  to  the  activation  of  hepatic  stellate  cells  and  their  production  of 
extracellular matrix proteins in the liver. An advanced stage of hepatic fibrosis is cirrhosis, in which 
functional  liver  tissue  is  largely  replaced  by  extracellular  matrix  and  regenerating  nodules  [175].  
The intestinal bacteria seem to be able to induce fibrotic liver disease by means of increased portal 
delivery of endotoxins, which leads to activation of Kuppfer cells, induction of production of TGF-β 
and subsequent activation of hepatic stellate cells [176]. The hepatic stellate cells appear to be the 
main precursors for myofibroblasts in the liver, and are the predominant targets through which TLR4 
ligands promote fibrogenesis.  
Minimal hepatic encephalopathy (MHE) is an important disorder in patients with cirrhosis, and a 
disorder that can seriously impair daily functioning and quality of life. Increased level of ammonia in 
the blood is most probably a key factor in the pathogenesis [177,178]. Treatment for 30 days with a 
preparation  consisting  of  four  different,  non-urease-producing  bacterial  strains  of  the  species 
Pediacoccus pentoseceus, Leuconostoc mesenteroides, L. paracasei subsp. paracasei and L. plantarum 
along with fermentable fibres was used for the management of MHE [99]. The patients had unusually 
high  faecal  loads  of  E.  coli  and  Staphylococcus  spp.,  and  the  probiotic  supplementation  with  the Nutrients 2011, 3  
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preparation of probiotics and fibres led to reduction of the viable count of E. coli and Staphylococcus, 
but  also  to  a  reduction  of  Fusobacterium  [99].  The  treatment  led  to  an  increased  proportion  of  
non-urease-producing Lactobacillus species and decreased ammonia levels in the blood, together with 
a reduction in the circulating levels of endotoxin. Decreased concentrations of serum bilirubin and 
ALT (alanine aminotransferase), as well as increases in serum albumin levels and prothrombin activity 
were  found  compared  to  pretreatment  values.  Also,  the  Child-Turcotte-Pugh  class  improved  in 
synbiotic-treated patients [99]. Alterations of the intestinal flora, improvement of the clinical status 
and lowered blood ammonia levels by the ingestion of probiotics without fibre supplementation has 
also been shown in previous studies [100–102].  
Early enteral nutrition with solutions containing fibres and probiotics have been suggested to reduce 
bacterial translocation and minimise the incidence of infections after liver transplantation in cirrhotic 
patients, and in a prospective, randomised placebo-controlled trial consisting of 95 patients, a marked 
decreased rate of postoperative infections was found [103,104]. 
3.4.3. Alcohol-Related Liver Injury 
Chronic ethanol consumption causes changes in the liver, including fatty liver, inflammation and 
cirrhosis [179], and is an established risk factor for the development of hepatocellular carcinoma in 
patients with liver cirrhosis [180]. Alcoholic steatohepatitis is characterised by infiltration of monocytes, 
macrophages, neutrophils, and lymphocytes, occurring as a consequence of activation of inflammatory 
mediators induced by TLR signalling [181,182]. During alcoholic steatohepatitis, serum TNF-α, IL-6, 
and IL-8 levels are increased and correlate with markers for the acute-phase response, liver function, 
and clinical outcome [183]. Ultrastructural abnormalities in the epithelial layer of the small intestine 
and a decreased gut barrier function can be seen in patients with cirrhosis [184–186]. Consequently, an 
impaired gut barrier function might be a cofactor in the progression of chronic liver damage. There is 
also a strict relationship between altered intestinal permeability and portal hypertension [187].  
Beneficial effects of probiotics have been reported in an open-label pilot trial, where patients with 
mild  alcoholic  hepatitis  consumed  Bifidobacterium  bifidum  and  L.  plantarum  [97].  The  treatment 
resulted  in  reduction  of  the  levels  of  alanine  aminotransferase  (ALT),  aspartate  aminotransferase 
(AST), gamma glutamyl transpeptidase, lactate dehydrogenase, and total bilirubin. The microbiota was 
also  affected  [97].  In  another  open-label  clinical  trial,  patients  with  alcoholic  cirrhosis  received  
L.  casei  Shirota  three  times  daily  for  four  weeks.  The  baseline  neutrophil  phagocytic  capacity  in 
patients was significantly lower compared to healthy controls, but was normalised at the end of the 
study. TLR2, TLR4 and TLR9 were over-expressed on the surface of neutrophils in patients, but at the 
end of the study, the expression of TLR4 was also normalised [98]. 
3.4.4. Non-Alcoholic Fatty Liver Disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of diseases ranging from simple 
steatosis  to  non-alcoholic  steatohepatitis  (NASH),  fibrosis,  and  cirrhosis.  In  its  initial  phase,  the 
healthy liver becomes steatotic mainly as a consequence of peripheral resistance to insulin, which 
increases the transport of fatty acids from adipose tissue to the liver. Steatosis renders hepatocytes 
susceptible to further obstacles. Once steatosis is established, other factors including gut-derived LPS, Nutrients 2011, 3  
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ethanol, oxidative stress and cytokines aggravate hepatocellular dysfunction, leading to an inflammatory 
process with hepatocellular degeneration and fibrosis [188]. NAFLD is associated with a number of 
diseases  such  as  obesity,  type  2  diabetes  mellitus,  hyperlipidaemia,  coeliac  disease,  exposure  to 
different  medications  and  environmental  toxins,  total  parenteral  nutrition  and  surgical  procedures 
(bypass of jejunum or ileum and other operations in the GI tract) [189,190]. The risk of NAFLD was 
also shown to be more evident in patients with a greater number of adenomatous polyps [191]. 
An endogenous factor that may contribute to the pathogenesis of NAFLD is the GI microbiota [192]. 
Hepatic oxidative stress may be increased by enhanced endogenous production of ethanol, and obese 
female NASH patients present higher levels of breath ethanol [193]. This may be caused by small 
intestinal bacterial overgrowth, which has been shown in patients with non-alcoholic steatohepatitis [194]. 
Intestinal  bacteria  may  also  affect  hepatic  oxidative  stress  through  release  of  LPS,  leading  to 
production of inflammatory cytokines by stimulation of luminal epithelial cells and Kupffer cells. 
Kupffer cells are the main source of TNF-α, a central mediator in the pathogenesis of NASH [195]. 
It  can  be  speculated  whether  probiotics  might  counteract  the  development  of  NAFLD  by,  for 
example, replacing aggravating bacteria in the GI tract, which in turn can decrease the production of 
proinflammatory  cytokines  like  TNF-α.  An  alternative  could  be  that  the  probiotic  bacteria  might 
improve the epithelial barrier function and thereby avoid exposure beyond the normal limit of LPS and 
ethanol to the liver. However, despite the rationale for the possible therapeutic role of probiotics, no 
controlled trials have been performed so far in patients with NAFLD/NASH [190]. However, the 
results achieved from two pilot studies seem promising. A combination of several bacterial strains with 
probiotic  potential  improved  routine  liver  damage  tests  and  plasma  levels  of  S-nitrosothiols, 
malondialdehyde  (MDA),  4-hydroxynonenal,  alanine  transaminase,  γ-glutamyltranspeptidase,  and 
TNF-α in NAFLD or NASH patients [95,96]. 
3.5. Ulcerative Colitis, Pouchitis and Colorectal Cancer 
Ulcerative colitis (UC) is characterised by periods of remission marked by episodes of clinical 
relapse caused by acute colonic and/or rectal inflammation. Treatment is primarily aimed at reducing 
inflammation during relapse and secondarily at prolonging the time spent in remission of clinical 
symptoms [196]. The histopathological features of UC are characterised by architectural distortion of 
colonic  crypts  with  frequent  depletion  of  mucin  from  the  goblet  cells  and  diffuse  infiltration  of 
lymphocytes and plasma cells.  
During the acute phase of inflammation, macrophages, neutrophils and eosinophils infiltrate the 
lamina propria of the colonic mucosa. Aggregating neutrophils, especially near the crypts, lead to the 
formation of abscesses [197]. Activated dendritic cells (DCs) and macrophages secrete cytokines that 
trigger and differentiate T cells, and activate the adaptive immune response. Increased populations of 
CD4-positive and CD8-positive cells have been found in the colonic lamina propria of patients with 
active  UC  [198].  Upon  antigenic  stimulation,  naive  CD4+  T  cells  are  activated,  expand  and 
differentiate into different effector subsets of cells (Th1, Th2 and Th17), that are characteristic for the 
production  of  distinct  cytokines  and  effector  functions  [199].  In  both  UC  and  Crohn’s  disease, 
polarised immune activity towards Th1 (marked by up-regulation of TNF-α, IL-1β, IFN-γ, IL-6) and 
Th17  (marked  by  IL-17  secretion)  response  is  reported,  while  UC  appears  to  exhibit  an  added Nutrients 2011, 3  
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contribution of Th2 responses (characterised by secretion of IL-4, IL-5, and IL-13) [200]. Cytokines, 
such as IFN-γ and TNF-α, increase the expressions of TLR4 in intestinal epithelial cells, which results 
in increased LPS responsiveness [201]. During UC, the expression of TLR4 is increased on mucosal 
DCs as well as on intestinal epithelial cells in inflamed and non-inflamed mucosa throughout the colon 
and terminal ileum [202,203]. The CD4+ T cell phenotype expressing CD25
high and fork-head box 
protein 3 (FoxP3) has been recognised as the functional representative of regulatory T cells (Treg). 
The Treg is known to down-regulate immune responses to both foreign and self-antigens [204] and a 
significant  number  of  T-regulatory  cells  can  be  found  in  the  inflamed  intestine.  Their  ability  to 
overcome the inflammatory response is hypothesised to be a major reason for remission, so is a major 
goal of therapies aimed at enabling the regulatory functions of these naturally immunosuppressive 
cells [199]. 
UC  patients  seem  to  have  higher  numbers  of  bacteria  associated  to  the  mucosa  than  healthy 
subjects, and the difference may reflect the altered nature of the mucus, which appears to be thinner 
and less sulphated than that of healthy subjects [205,206]. A thin mucus layer containing larger than 
normal  numbers  of  bacteria  might  facilitate  contact  between  bacterial  antigens  and  the  mucosal 
immune system. 
The intestinal microbiota in patients with active UC has been shown to be less diverse than in 
healthy subjects [207]. It is not clear whether endogenous intestinal bacteria and/or specific bacterial 
pathogens are directly or indirectly involved in the initiation and/or maintenance of UC. Neither is it 
known which bacterial components or antigens can be responsible for the unrestrained inflammatory 
response. The colonic surface and the inflamed area of UC patients are colonised by a wide variety of 
organisms [58]. The Clostridium histolyticum/Clostridium lituseburense group made up 21% of the 
microbiota in UC specimens, while these organisms were not found in controls. These phylogenetic 
groups contain mainly clostridia belonging to clusters I and II, and part of cluster XI of Collins [54], 
species such as C. histolyticum, Clostridium beijerinckii, Clostridium perfringens, Clostridium botulinum, 
Clostridium intestinalis or Clostridium lituseburense, C. difficile, Clostridium bifermentans. Several of 
these organisms may be pathogenic. Enterobacteriaceae have also been considered as being involved 
in the pathogenesis of UC, owing to the ability to adhere to the intestinal mucosa and to produce 
enterotoxins [208]. E. coli and Klebsiella accounted for 25% of the mucosa-associated and 20% of the 
mucosa penetrating bacteria [58]. High proportions of Enterobacteriaceae and B. fragilis, together 
with a substantial presence of Pseudomonas aeruginosa were found on the inflamed colonic mucosa 
taken during surgery from a 12-year-old girl suffering from UC [60]. Sulphate-reducing bacteria have 
received attention due to their ability to reduce sulphate to sulphide, a by-product of their respiration. 
Hydrogen  sulphide  is  freely  permeable  to  cell  membranes  and  inhibits  butyrate  oxidation  in 
colonocytes [209], and hydrogen sulphide has been implicated in the pathogenesis of UC [210].  
The number of lactobacilli seems to be relatively low in active UC [211]. However, lactobacilli 
were predominantly detected in inactive patients, and were suggested to have a role in the induction of 
remission [212]. It has been hypothesised that the changing condition in the intestine may influence the 
amount as well as the type of Lactobacillus [213,214].  
The use of probiotics for patients suffering from UC has gained attention, and studies to verify the 
efficiency have been performed for both intervention and maintenance therapy. A meta-analysis to 
evaluate  the  induction  of  remission  and  maintenance  of  probiotic  therapy  was  carried  out  by  Nutrients 2011, 3  
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Sang et al. [215] on thirteen randomised, controlled studies. It was concluded that probiotics were 
more effective than placebo in maintaining remission [215].  
The  probiotic  mixture,  VSL#3  for  treatment  of  mild-to-moderate  active  UC,  was  analysed  by  
Sood et al. [123]. Six weeks of probiotic treatment resulted in a significantly higher percentage of 
patients with more than 50% improvement in UC Disease Activity Index score, and after 12 weeks, 
significantly more patients achieved remission [123].  
Several species and strains of bacteria with claimed probiotic potential have been used in clinical 
trials, e.g., E. coli Nissle [127], a mixture of L. casei, L. plantarum, L. acidophilus, L. delbrueckii 
subsp.  bulgaricus,  Bifidobacterium  longum,  Bifidobacterium  breve,  Bifidobacterium  infantis  and 
Streptococcus  salivarius  subsp.  thermophilus  (VSL#3)  [122,123,124],  a  mixture  of  Streptococcus 
faecalis,  Clostridium  butyricum,  and  Bacillus  mesentericus  (BIO-THREE)  [126],  a  mixture  of 
L. rhamnosus  and  L.  reuteri  [128],  L.  rhamnosus  GG  [129],  B.  breve  strain  Yakult,  B.  bifidum  
strain  Yakult  and  L.  acidophilus  [130].  Probiotics  have  shown  effects  in  treatment  of  active  
mild-to-moderate  UC  by  decreasing  clinical  activity  index,  preventing  relapse,  and  induction  of 
remission  [123,124,126–130].  Also,  improvements  of  histological  scores  and  increases  in  faecal 
butyrate,  propionate  and  short-chain  fatty  acid  concentrations  have  been  registered  [130]. 
Consumption of probiotics by UC patients prevented flare-ups and induced depressed activation of the 
transcriptional  factor  NF-κB,  decreased  expressions  of  TNF-α  and  IL-1β,  while  the  expression  of  
IL-10  was  elevated  [131].  The  percentage  of  CD4+CD25
high  cells  increased  in  IBD  patients  after 
ingestion of a probiotic yogurt [128]. Not much data is available on how probiotics might alter the 
composition of the resident gut microbiota but it seems that some probiotics can increase the load of 
lactobacilli and/or bifidobacteria [126,131].  
Ileal pouch-anal anastomosis is a surgical procedure for management of UC by making an ileal 
reservoir, a pouch. Unfortunately, a complication frequently occurring is inflammation in the pouch, 
pouchitis [216]. A meta-analysis of five randomised, placebo-controlled clinical trials indicated an 
advantage of probiotic administration in the treatment of pouchitis [217]. Pouchitis disease activity 
index  scores,  as  well  as  the  inflammatory  bowel  disease  questionnaire  score,  were  improved  and 
remission maintenance fulfilled [122,125]. Furthermore, Pronio et al. [122] found increased percentages 
CD4+CD25
high cells, CD4+ LAP-positive cells (latency-associated peptide) and a significant reduction 
in IL-1β mRNA expression in mucosal samples. Since an increase in Foxp3 mRNA expression was 
also found in mucosal biopsis, this indicates higher numbers of regulatory T cells [122]. 
The pouch microbiota after probiotic treatment indicated higher bacterial diversity and lower fungal 
diversity  during  remission  induced  by  probiotic  consumption  [218].  The  opposite  was  found  for 
control  patients  developing  pouchitis.  A  recolonisation  and  diversification  of  the  lactobacilli  and 
bifidobacteria was shown at remission [218].  
A variety of hepatobiliary abnormalities have been described in patients with ulcerative colitis, 
including  fatty  changes,  cholelithiasis,  pericholangitis,  primary  sclerosing  cholangitis,  cirrhosis, 
chronic active hepatitis, amyloidosis, and bile duct cancer, with primary sclerosing cholangitis being 
the most common form [219]. Because gut-derived components are easily accessible to the liver via 
the portal vein, it is suggested that increases in the permeability of the intestinal epithelium during 
inflammation allow bacterial antigens and toxins to enter the lamina propria and cause an inflammatory Nutrients 2011, 3  
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reaction when the bacterial products reach the liver [220]. However, no clinical trials on the effect of 
probiotics on ulcerative colitis-associated liver injuries seem to have been done.  
Patients with ulcerative colitis also represent a risk group for developing colorectal cancer (CRC). 
The two most important risk factors seem to be the duration and extent of the disease but the severity 
of  inflammation  has  also  been  shown  to  correlate  with  an  increased  frequency  of  dysplasia  and 
therefore a greater CRC risk [221]. Probiotics have been given preoperatively and postoperatively to 
CRC patients in order to reduce intestinal pathogens and to modulate immune response. A mixture of 
B.  longum  and  Lactobacillus  johnsonii  in  a  dose  of  10
9  CFU  decreased  the  concentration  of 
Enterobacteriacae in faeces while a dose of 10
7 CFU failed to do so [222]. The same trend was found 
for enterococci [222]. The ratio of Bifidobacterium/E. coli increased in patients given probiotics with 
enteral nutrition before colorectal cancer resection [132]. Both preoperative and postoperative ratios 
were significantly lower in the control group. Nine days after surgery, faecal concentration of SIgA 
increased, but serum IgG, IgM, IgA, IL-6, CRP concentrations decreased. Furthermore, the probiotic 
treatment also caused less postoperative septic complications [132]. 
3.6. Crohn’s Disease 
Similar symptoms may appear during Crohn’s disease (CD) and UC that can give rise to diagnostic 
difficulties [223]. However, some specific characteristics reflect the different conditions. CD can affect 
any part of the gastrointestinal tract and the inflammation is transmural and influences the whole 
intestinal wall [224] while UC mostly affects the superficial lining mucosa in colon and rectum. UC 
usually  begins  in  the  rectum  and  extends  upwards  through  colon  and  rarely  affects  the  small  
intestine  [225].  The  inflammation  in  UC  has  a  continuous  distribution  while  CD  has  a  patchy  
pattern [224]. Analysis of bacterial 16S rRNA genes revealed no significant differences in mucosal 
bacterial composition between CD and UC patients [226], but a trend towards a larger reduction of 
diversity was found in UC patients but it was not significant compared to CD patients [226]. Also, a 
trend has been seen towards a predominance of Bacteroides and an increase of mucosal bacteria in CD 
patients [227]. 
The  efficacy  of  probiotics  for  induction  of  remission  in  Crohn’s  disease  was  evaluated  by 
Butterworth et al. [228] through data bases and register-searching of randomised controlled clinical 
trials.  Twelve  potentially  relevant  studies  were  identified  but  eleven  were  not  considered  to  fit  
the  stated  criteria.  One  study  fulfilled  the  inclusion  criteria  but  it  only  included  11  patients  with  
moderate- to active-Crohn’s disease [115]. The patients received L. rhamnosus GG for six months and 
they  were  also  given  antibiotics  one  week  before  the  probiotic/placebo  treatment  was  initiated. 
Sustained remission was the principal endpoint but no significant difference in median time to relapse 
was observed between placebo and treatment group [115].  
Children with CD in remission were given L. rhamnosus GG in addition to standard therapy in 
order  to  try  to  prolong  this  state  [116].  However,  no  prolonged  remission  was  obtained  [116]. 
Ineffectiveness  of  remaining  remission  by  supplementation  of  probiotics  was  also  found  by 
administration  of  L.  johnsonii  LA1  after  surgical  resection  [120,121]  or  by  administration  of 
L. rhamnosus  GG  to  adults  [117].  In  contrast  to  these  negative  results,  preliminary  data  on  four 
paediatric  patients  showed  significant  improvement  by  administration  of  L.  rhamnosus  GG  [118]. Nutrients 2011, 3  
 
665 
Another small prospective study was performed on four children with Crohn´ s disease. The patients 
were given L. rhamnosus GG, and a significant improvement in clinical activity and improved barrier 
function of the intestine was found [119]. These small pilot studies are needed in order to find an 
efficient probiotic strain and to provide a base for the estimation of power, in order to be able to 
include a reasonable number of patients in an extended study. This extended, hypothetical study ought 
to be a blinded placebo-controlled study, running over a time period clinically relevant for the disease, 
i.e., the study will be costly and involve serious ethical considerations as a number of patients in such a 
study will receive a product with no therapeutic effects, and preferably the patients should give up 
other therapies during the study period. Consequently, in this case, the probiotics must be regarded as a 
medical drug and not as a supplement of functional foods. If the intention is to evaluate the probiotic 
effect for a certain bacterial strain intended as ingredient in functional foods, patients with Crohn’s 
disease hardly form the best test group. 
3.7. Radiation-Induced Enteritis 
Intestinal  injury  from  radiotherapy  of  pelvic  malignancies  is  clinically  important,  as  enteritis 
symptoms commonly occur and there are few therapeutic options. Moreover, it has been suggested that 
protection from injury of normal tissues may provide an increase in tumour control, by allowing an 
increase  in  the  radiation  dose  [229,230].  Since  the  GI  mucosa  contains  sensitive  regenerative 
epithelium susceptible to the toxic effects of ionising radiation, injury to the small and large intestine is 
among the most significant complications encountered in patients receiving radiation directed at the 
abdominal or pelvic cavity [231,232].  
The radiation dose that can be applied in clinical practice is usually limited by the need to restrict 
the number and severity of side effects in normal tissues surrounding a tumour, which are unavoidably 
exposed to radiation [233]. Acute radiation enteritis is a potentially serious complication of radiation 
therapy.  Histologically  detectable  alterations  of  the  intestinal  mucosa,  like  protein  and  fibrin 
precipitation,  inflammation  and  oedema  of  the  bowel  wall,  can  be  found  several  days  after  
radiation [234,235]. The villous height and number decreases. The affected functioning of the bowel 
mucosa leads to the loss of proteins, electrolytes and water. Due to the reduced intestinal surface, 
conjugated bile salts are not reabsorbed in the small intestine and enter the colon. Local bacterial flora 
deconjugates the bile salts leading to chologenic diarrhoea [236,237].  
An  early  inflammatory  response,  beginning  a  few  hours  after  irradiation,  is  characterised  by 
leucocyte  infiltration  into  the  irradiated  organs.  Radiation  activates  various  cellular  signalling 
pathways  that  lead  to  expression  and  activation  of  pro-inflammatory  and  pro-fibrotic  cytokines, 
vascular injury and activation of the coagulation cascade. Certain mucosal cytokines are activated and 
the levels of TNF-α, IL-1β, IL-2, IL-6, and IL-8 are significantly higher [238]. 
Radiation  influences  and  disturbs  the  mucosal  microbiota,  leading  to  a  translocation  of 
microorganisms or microbial products through the mucosa into the blood circulation [239]. Mucosal 
permeability of irradiated colon of patients treated for rectal cancer can be expected to be increased. 
This difference may be attributed to the mucosal atrophy observed in the irradiated patients and may 
result in an increased risk of radiation enteritis [232]. Translocation of pathogenic organisms through Nutrients 2011, 3  
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the intestinal wall into the bloodstream, the peritoneal cavity and abdominal organs is a well-recognised 
cause of supervening sepsis and life-threatening complications in critically ill patients [240]. 
Clinical trials have implicated probiotic therapy as beneficial against radiation-induced diarrhoea.  
A double-blind, placebo-controlled clinical trial including almost 500 patients who underwent adjuvant 
postoperative  radiation  therapy  after  surgery  for  sigmoid,  rectal,  or  cervical  cancer  has  been  
performed [133]. The patients were assigned to either a probiotic preparation (VSL#3) or placebo 
treatment,  starting  from  the  first  day  of  radiation  therapy.  The  incidence  and  severity  of  
radiation-induced diarrhoea, the daily numbers of bowel movements, and the use of loperamide were 
all  reduced  [133].  Improved  stool  consistency  and  reduced  number  of  bowel  movements,  less 
abdominal discomfort, and fewer chemotherapy-dose reductions due to toxicity have also been found 
by the use of L. rhamnosus [134,135]. Administration of L. acidophilus during irradiation of the pelvic 
area  because  of  gynaecological  malignancies  also  appeared  to  prevent  radiotherapy-associated 
diarrhoea [136]. Flatulence was increased though, probably due to lactulose given as substrate for the 
bacteria  [136].  In  contrast,  it  was  found  for  gynaecological  malignancies  that  the  incidence  of 
radiation-induced diarrhoea was not reduced by the use of L. casei [137]. However, a significant effect 
on stool consistency was recorded [137].  
4. Conclusions 
For most of the examples of probiotic applications mentioned in the present review there is a large 
amount of evidence on effects and mechanisms in experimental animal models, but human studies in 
most cases are still relatively rare. The present review has only dealt with observations in humans, and 
it is obvious that more clinical trials are needed to examine and verify the anti-inflammatory effects of 
probiotics in regulating systemic inflammation and local mucosal inflammation, and immune-regulation 
of other dysfunctional immune reactions leading to, for example, allergy and autoimmune diseases. On 
the other hand, it is also obvious that the resident microbiota from mouth to rectum is an important 
factor  for  homeostasis  and  for  the  patho-physiological  course  of  events,  and  that  probiotics  are 
promising means of intervention. Popular species for use as probiotics are L. paracasei, L. rhamnosus, 
L.  acidophilus,  L.  johnsonii,  L.  fermentum,  L.  reuteri,  L.  plantarum,  B.  longum  and  B.  animalis. 
However, the phylogenetic differences between these taxa can be huge. There are extremely large 
variations  between  Lactobacillus  and  Bifidobacterium,  but  the  phylogenetical  differences  are  also 
substantial between many of the different Lactobacillus spp., for example between L. acidophilus,  
L. fermentum, L. reuteri and L. plantarum. Even within different strains of the same species, the 
genomic differences can be considerable. Consequently, when the major genomic differences between 
different types of probiotics are taken into account, it is to be expected that the human body can 
respond differently to the different species and strains. This fact does not always seem have been 
considered when testing probiotics in humans, and the often huge genomic differences and resultant 
differences in phenotype is neglected in the discussion of the outcome of human trials with probiotics. 
From scientific and clinical perspectives it is of utmost importance to choose good endpoints in 
human trials with probiotics, i.e., endpoints that beyond dispute show improvement in health status. 
Examples  of  such  endpoints  can  be  the  blood  pressure  in  subjects  suffering  from  the  metabolic 
syndrome, or decrease in liver fat in subjects with fatty liver. On the other hand, these types of hard Nutrients 2011, 3  
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endpoint may be regarded as too clinical by the legislative authorities if the study is to be used for 
claiming health benefits for foods or food supplements. In this realm, biological markers for health 
seem to be more acceptable. The problem here is to find good markers, e.g., immunological markers. 
An obstacle is that the immune system is a double-edged sword—in one setting, inflammation is 
required  and  an  increased  concentration  of  inflammatory  markers  is  a  sign  of  a  properly  acting 
immune defence, but in another setting inflammation is something negative and increased levels of 
inflammatory  markers  indicate  a  dysfunction  in  the  body.  Furthermore,  the  concentrations  of 
immunological  markers  change  with  time—they  interact  with  each  other  and  they  mostly  have 
multiple functions. On the basis of Table 2, IL-6, IL-10 (ought to be supplemented with IL-12) and 
IgA are immunological markers that seem to have been affected in more than one study. However, the 
markers  affected  and  considered  relevant  for  systemic  inflammation  vary  between  the  individual 
studies and between different categories of dysfunctions. A suggestion for future studies on systemic 
inflammation is to include, as a  minimum, measurements of C-reactive protein (CRP), fibrinogen  
and  IL-6,  combined  with  the  liver-function  markers  alanine-aminotransferase  (ALAT)  and  
aspartate-aminotransferase (ASAT). These are all markers that frequently are used in clinical settings, 
and they are reasonably robust. Also, highly relevant are different categories of white blood cells  
and  certain  key-receptors  for  inflammation,  e.g.,  Foxp3  (regulatory  T  cells),  Cd11b  and  CD11c 
(macrophages and dendritic cells) and unravelling different colonic macrophage and dendritic cell 
populations and their functions is of high interest. Furthermore, their TLR2 and TLR4 expression, but 
also the expression on epithelial cells is an option for clarifying bacterial stimulation. Other useful 
markers for the inflammatory status of the intestinal mucosa are calprotectin, IgA, myeloperoxidase 
(MPO), and an incontrovertible end-point is a histopathological evaluation.  
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